

Alpelisib for *PIK3CA*-Mutated, Hormone Recepto

New England Journal of Medicine

380, 1929-1940

DOI: 10.1056/nejmoa1813904

Citation Report

#	ARTICLE	IF	CITATIONS
2	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. <i>Breast Cancer Research</i> , 2019, 21, 90.	2.2	81
3	Alpelisib for <i>PIK3CA</i> -Mutated Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 686-687.	13.9	15
4	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019, 30, 1541-1557.	0.6	464
5	PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 659-667.	1.1	17
6	Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes. <i>Annals of Surgical Oncology</i> , 2019, 26, 3344-3353.	0.7	15
7	Alpelisib: First Global Approval. <i>Drugs</i> , 2019, 79, 1249-1253.	4.9	170
8	Management of toxicity to isoform $\beta$ -specific PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x21-x26.	0.6	70
9	Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Drugs</i> , 2019, 79, 1849-1866.	4.9	36
10	Practical Concepts, Current Challenges, and Technological Advances in Clinical Next-Generation Sequencing Assays for Solid Tumors. <i>Advances in Molecular Pathology</i> , 2019, 2, 163-175.	0.2	0
11	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	2.3	55
12	Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets. <i>European Journal of Cancer</i> , 2019, 121, 202-209.	1.3	11
13	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	2.2	21
14	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3K $\beta$ inhibitors. <i>Science</i> , 2019, 366, 714-723.	6.0	185
15	Double trouble for cancer gene. <i>Science</i> , 2019, 366, 685-686.	6.0	4
16	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6598-6605.	3.2	17
17	Update Breast Cancer 2019 Part 5 "Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1090-1099.	0.8	16
18	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	11
19	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617.	1.4	24

#	ARTICLE	IF	CITATIONS
20	CDK4/6 inhibitors in advanced breast cancer, what is beyond?. <i>Oncology Reviews</i> , 2019, 13, 416.	0.8	6
21	Precision medicine: PI3K targeting in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 479-479.	1.1	0
22	New strategies for the precision treatment of HER2-driven tumours. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 239-249.	0.4	0
23	HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques. <i>PLoS ONE</i> , 2019, 14, e0220906.	1.1	5
24	An evaluation of fulvestrant for the treatment of metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1819-1829.	0.9	18
25	The current status of the clinical utility of liquid biopsies in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1031-1041.	1.5	27
26	Available and emerging molecular markers in the clinical management of breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 919-928.	1.5	9
27	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	5.1	131
28	Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies. <i>Analytical Chemistry</i> , 2019, 91, 13105-13111.	3.2	29
29	Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer. <i>Molecular and Cellular Oncology</i> , 2019, 6, e1625620.	0.3	2
30	Outstanding Issues with Umbrella and Basket Studies. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1685-1688.	0.5	1
31	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620
32	Alpelisib effective in advanced-stage disease. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 466-466.	12.5	2
35	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. <i>Cancers</i> , 2019, 11, 1661.	1.7	48
36	Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. <i>Breast Cancer Research</i> , 2019, 21, 146.	2.2	52
37	Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. <i>Cancers</i> , 2019, 11, 1987.	1.7	12
38	Efficacy of PI3K inhibitors in advanced breast cancer. <i>Annals of Oncology</i> , 2019, 30, x12-x20.	0.6	145
39	Overview of the relevance of PI3K pathway in HR-positive breast cancer. <i>Annals of Oncology</i> , 2019, 30, x3-x11.	0.6	92

#	ARTICLE	IF	CITATIONS
40	Targeting PI3KCA pathway to improve patient outcomes in hormone receptor-positive breast cancer: a worthy 20-year wager?. <i>Annals of Oncology</i> , 2019, 30, x1-x2.	0.6	2
41	PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5792.	1.8	65
42	A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309.	13.7	1,391
43	Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. <i>PLoS ONE</i> , 2019, 14, e0226853.	1.1	39
44	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x27-x42.	0.6	63
45	Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1309-1319.	0.8	11
46	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26823-26834.	3.3	103
47	Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989410.	1.4	17
48	PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3K Inhibitors in Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 72-85.	7.7	154
49	Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 292-303.	1.9	9
50	Mechanisms of resistance to estrogen receptor modulators in ER+/HER2 <sup>-</sup> advanced breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 559-572.	2.4	19
51	Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2 <sup>-</sup> Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 1-11.	1.1	20
52	The potential of ctDNA analysis in breast cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 54-72.	2.7	22
53	The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. <i>Nature Reviews Cancer</i> , 2020, 20, 74-88.	12.8	1,087
54	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. <i>Cancer</i> , 2020, 126, 1274-1282.	2.0	37
55	Whole exome sequencing of cell-free DNA – A systematic review and Bayesian individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 83, 101951.	3.4	26
56	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020, 65, 51-64.	4.3	63
57	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS study. <i>American Journal of Hematology</i> , 2020, 95, 362-371.	2.0	102

#	ARTICLE	IF	CITATIONS
58	Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1340-1347.	1.3	25
59	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	1.1	5
60	Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. <i>Breast Care</i> , 2020, 15, 408-414.	0.8	13
61	Genomic Characterization of HPV-related and Gastric-type Endocervical Adenocarcinoma: Correlation With Subtype and Clinical Behavior. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 578-586.	0.9	32
62	Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 687-697.	1.1	13
63	Systemic investigations into the molecular features of bilateral breast cancer for diagnostic purposes. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 41-47.	1.5	5
64	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	3.2	91
65	Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. <i>Gynecologic Oncology</i> , 2020, 156, 203-210.	0.6	27
66	PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. <i>Biochemical Pharmacology</i> , 2020, 172, 113729.	2.0	174
67	Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 273-281.	0.8	4
68	Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. <i>Cell Systems</i> , 2020, 10, 66-81.e11.	2.9	26
69	A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e232-e243.	1.1	29
70	Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020. <i>Breast Journal</i> , 2020, 26, 69-80.	0.4	31
71	In the literature: February 2020. <i>ESMO Open</i> , 2020, 5, e000680.	2.0	0
72	Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 441-443.	7.7	4
73	PIK3CA and Breast Cancer. <i>Advances in Molecular Pathology</i> , 2020, 3, 189-198.	0.2	0
74	CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3214.	1.0	6
75	Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression. <i>Molecular Cell</i> , 2020, 80, 279-295.e8.	4.5	14

#	ARTICLE	IF	CITATIONS
76	Glyoxalase 1 expression analysis by immunohistochemistry in breast cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153257.	1.0	3
77	The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2463-2474.	1.1	10
78	Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 1594-1596.	0.6	1
79	Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. <i>Annals of Oncology</i> , 2020, 31, 1709-1718.	0.6	86
80	Metabolic Imaging Detects Resistance to PI3K Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 516-533.e9.	7.7	38
81	Developing themes in targeted therapies for hormone receptor-positive breast cancer. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2020, 15, 15-23.	0.6	0
83	Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. <i>PLoS ONE</i> , 2020, 15, e0237802.	1.1	223
84	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 1217-1223.	1.5	1
85	Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions. <i>BMC Cancer</i> , 2020, 20, 944.	1.1	9
86	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
87	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 943-953.	1.9	19
88	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103119.	2.0	97
89	Discovery and SAR of Novel Disubstituted Quinazolines as Dual PI3K/mTOR Inhibitors Targeting Breast Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2156-2164.	1.3	8
90	PIK3CA mutations matter for cancer in dogs. <i>Research in Veterinary Science</i> , 2020, 133, 39-41.	0.9	12
91	In the literature: June 2020. <i>ESMO Open</i> , 2020, 5, e000832.	2.0	0
92	Molecular alterations in meningioma: prognostic and therapeutic perspectives. <i>Current Opinion in Oncology</i> , 2020, 32, 613-622.	1.1	51
93	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
94	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. <i>Advances in Biological Regulation</i> , 2020, 78, 100758.	1.4	21

#	ARTICLE	IF	CITATIONS
95	Management of hormone receptor-positive, HER2-negative early breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 187-200.	0.8	24
96	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , 2020, 583, 620-624.	13.7	198
97	PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer. <i>Drug Discovery Today</i> , 2020, 25, 1762-1771.	3.2	25
98	Fulvestrant plus capivasertib for metastatic breast cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e234.	5.1	1
99	Cross-species oncogenic signatures of breast cancer in canine mammary tumors. <i>Nature Communications</i> , 2020, 11, 3616.	5.8	58
101	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45
102	Comprehensive Mapping of Key Regulatory Networks that Drive Oncogene Expression. <i>Cell Reports</i> , 2020, 33, 108426.	2.9	14
103	Optimal Clinical Management and the Molecular Biology of Angiosarcomas. <i>Cancers</i> , 2020, 12, 3321.	1.7	15
104	Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 580251.	1.6	38
105	Diabetic Ketoacidosis Associated With Alpelisib Treatment Of Metastatic Breast Cancer. <i>AACE Clinical Case Reports</i> , 2020, 6, e349-e351.	0.4	19
106	PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9189.	1.8	32
107	Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. <i>Molecules</i> , 2020, 25, 5686.	1.7	19
108	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. <i>Nature Communications</i> , 2020, 11, 5679.	5.8	41
109	Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1115-1122.	0.8	11
111	Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 357-364.	1.1	5
112	Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.	5.7	29
113	Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094093.	1.4	55
115	Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives. <i>Cancers</i> , 2020, 12, 2001.	1.7	2

#	ARTICLE	IF	CITATIONS
116	Clinical implications of breast cancer tumor genomic testing. <i>Breast Journal</i> , 2020, 26, 1565-1571.	0.4	3
117	New drug approvals for 2019: Synthesis and clinical applications. <i>European Journal of Medicinal Chemistry</i> , 2020, 205, 112667.	2.6	36
118	Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper. <i>Current Oncology Reports</i> , 2020, 22, 98.	1.8	3
119	Landscape of circulating tumour DNA in metastatic breast cancer. <i>EBioMedicine</i> , 2020, 58, 102914.	2.7	40
120	Pan-cancer image-based detection of clinically actionable genetic alterations. <i>Nature Cancer</i> , 2020, 1, 789-799.	5.7	343
121	Activating PIK3CA mutation promotes adipogenesis of adipose-derived stem cells in macrodactyly via up-regulation of E2F1. <i>Cell Death and Disease</i> , 2020, 11, 600.	2.7	7
122	Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 123-133.	1.1	2
123	Testing considerations for phosphatidylinositol 3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer. <i>Cancer Medicine</i> , 2020, 9, 6463-6472.	1.3	9
124	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 89, 102069.	3.4	32
125	Neuroendocrine breast carcinoma: a rare but challenging entity. <i>Medical Oncology</i> , 2020, 37, 70.	1.2	27
126	Novel targeted therapies for metastatic breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 907-907.	0.7	10
127	Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 89.	2.2	74
128	Copanlisib in the treatment of non-Hodgkin lymphoma. <i>Future Oncology</i> , 2020, 16, 1947-1955.	1.1	11
129	Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 583314.	1.3	7
130	Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15094-15114.	2.9	52
132	PtdIns(3,4,5)P3-dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28056-28067.	3.3	11
133	Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection. <i>AAPS Journal</i> , 2020, 22, 134.	2.2	13
135	Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2338-2345.	0.9	8



#	ARTICLE	IF	CITATIONS
136	Targeting Autophagy in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7836.	1.8	54
137	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. <i>Nature Communications</i> , 2020, 11, 5488.	5.8	25
138	PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come. <i>ESMO Open</i> , 2020, 5, e000890.	2.0	8
139	Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood. <i>Current Treatment Options in Oncology</i> , 2020, 21, 89.	1.3	2
140	Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer. <i>PLoS ONE</i> , 2020, 15, e0238262.	1.1	15
141	The Future of ER+/HER2 <sup>-</sup> Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors. <i>Anticancer Research</i> , 2020, 40, 4829-4841.	0.5	21
142	Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor <sup>+</sup> positive metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 2661-2672.	1.1	6
143	Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1475.	1.3	11
144	Genomic Signatures in Luminal Breast Cancer. <i>Breast Care</i> , 2020, 15, 355-365.	0.8	20
145	Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. <i>Personalized Medicine</i> , 2020, 17, 399-420.	0.8	7
147	ctDNA as a cancer biomarker: A broad overview. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103109.	2.0	128
148	Management of ER positive metastatic breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 270-277.	0.8	25
149	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor <sup>+</sup> positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6141-6148.	3.2	6
150	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6254-6265.	3.2	22
151	Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors <sup>+</sup> proceedings from breast cancer expert group meeting. <i>Chinese Clinical Oncology</i> , 2020, 9, 61-61.	0.4	4
152	Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians. <i>Cancers</i> , 2020, 12, 2390.	1.7	21
153	PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. <i>Scientific Reports</i> , 2020, 10, 12308.	1.6	20
154	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171

#	ARTICLE	IF	CITATIONS
155	The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease. <i>Kidney International</i> , 2020, 98, 883-896.	2.6	14
156	PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24427-24433.	3.3	12
157	Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 1076-1089.	0.6	4
158	Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1274, 203-222.	0.8	16
159	Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 923-926.	1.0	3
160	Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. <i>Current Genetic Medicine Reports</i> , 2020, 8, 109-119.	1.9	0
161	Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. <i>Drugs</i> , 2020, 80, 1685-1697.	4.9	72
162	Hyperinsulinaemia in cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 629-644.	12.8	122
163	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. <i>Lancet Oncology</i> , The, 2020, 21, 1296-1308.	5.1	196
164	Chemotherapy for the Management of Cerebral Metastases. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 603-611.	0.8	5
165	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. <i>Genome Medicine</i> , 2020, 12, 78.	3.6	10
166	Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell Level PI3K Pathway Activation. <i>Clinical Cancer Research</i> , 2020, 26, 5903-5913.	3.2	8
167	Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression. <i>Cancers</i> , 2020, 12, 2231.	1.7	34
168	Understanding genomics and the immune environment of penile cancer to improve therapy. <i>Nature Reviews Urology</i> , 2020, 17, 555-570.	1.9	36
169	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2020, 22, 91.	2.2	32
170	Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa078.	0.4	12
171	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. <i>Breast Care</i> , 2020, 15, 608-618.	0.8	8
172	Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9457.	1.8	56

#	ARTICLE	IF	CITATIONS
173	PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 673-680.	0.3	2
174	Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function. <i>Frontiers in Endocrinology</i> , 2020, 11, 591217.	1.5	30
175	Utility of Circulating Tumor DNA in Different Clinical Scenarios of Breast Cancer. <i>Cancers</i> , 2020, 12, 3797.	1.7	4
176	Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review. <i>Epigenomes</i> , 2020, 4, 27.	0.8	6
177	Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2557-2570.	13.9	146
178	Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100033.	0.1	1
180	Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 251-258.	1.0	10
181	Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?. <i>Life</i> , 2020, 10, 325.	1.1	8
182	A Case for Phosphoinositide 3-Kinase-Targeted Therapy for Infectious Disease. <i>Journal of Immunology</i> , 2020, 205, 3237-3245.	0.4	6
184	Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8062.	1.8	103
185	Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2020, 15, 723-732.	1.7	6
186	Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .		1
187	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	3.4	4
188	A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e1604-e1613.	1.9	9
189	Cyclin-dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor-positive breast cancer patients: A systematic review and meta-analysis of randomized clinical trials. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100175.	0.7	7
190	Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials. <i>ESMO Open</i> , 2020, 5, e000653.	2.0	5
191	Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?. <i>Current Oncology Reports</i> , 2020, 22, 57.	1.8	26
192	Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice. <i>Cancers</i> , 2020, 12, 1156.	1.7	21

#	ARTICLE	IF	CITATIONS
193	Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. <i>Annals of Oncology</i> , 2020, 31, 1001-1010.	0.6	99
194	Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. <i>Cancer</i> , 2020, 126, 3400-3416.	2.0	19
195	What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	1.8	13
196	Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3528.	1.8	30
198	Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Chinese Medical Journal</i> , 2020, 133, 1099-1108.	0.9	17
199	Preanalytical variables that affect the outcome of cell-free DNA measurements. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 484-507.	2.7	52
200	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	2.2	175
201	The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas. <i>Oncologist</i> , 2020, 25, e1318-e1329.	1.9	19
202	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 491-502.	1.1	2
203	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. <i>Scientific Reports</i> , 2020, 10, 8867.	1.6	13
204	Speeding tumor genotyping during the SARS-CoV-2 outbreak through liquid biopsy. <i>Cancer</i> , 2020, 126, 4089-4091.	2.0	9
205	Cell free DNA biology and its involvement in breast carcinogenesis. <i>Advances in Clinical Chemistry</i> , 2020, 97, 171-223.	1.8	6
206	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	5.7	23
207	Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. <i>Cancer Science</i> , 2020, 111, 2174-2182.	1.7	16
208	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e292-e308.	1.8	3
209	The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102988.	2.0	25
210	Targeting Protein Synthesis in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1298.	1.7	32
211	<p></p>Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3477-3487.	0.9	40

#	ARTICLE	IF	CITATIONS
212	Senescence as a therapeutically relevant response to CDK4/6 inhibitors. <i>Oncogene</i> , 2020, 39, 5165-5176.	2.6	73
213	Regulation of breast cancer metastasis signaling by miRNAs. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 837-886.	2.7	87
214	Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. <i>Cancers</i> , 2020, 12, 1404.	1.7	78
215	Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 500-513.	1.0	7
216	Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. <i>EClinicalMedicine</i> , 2020, 21, 100332.	3.2	80
217	Palbociclib and beyond for the treatment of HR <sup>+</sup> /HER2 <sup>-</sup> metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors. <i>Current Medical Research and Opinion</i> , 2020, 36, 1363-1373.	0.9	5
218	Metastatic breast cancer patient perceptions of somatic tumor genomic testing. <i>BMC Cancer</i> , 2020, 20, 389.	1.1	8
219	Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 945-954.	1.0	11
220	Pharmacological management of male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1493-1504.	0.9	3
222	Discovery of 3-Quinazolin-4(3 <i>H</i> )-on-3-yl-2,2-dimethylpropanamides as Orally Active and Selective PI3K $\alpha$ Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1463-1469.	1.3	4
223	The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1226-1239.	7.7	32
224	A Multiplex PCR-Based Next Generation Sequencing-Panel to Identify Mutations for Targeted Therapy in Breast Cancer Circulating Tumor Cells. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3364.	1.3	4
225	The therapeutic response of ER <sup>+</sup> /HER2 <sup>-</sup> breast cancers differs according to the molecular Basal or Luminal subtype. <i>Npj Breast Cancer</i> , 2020, 6, 8.	2.3	27
227	Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance. <i>Clinical Cancer Research</i> , 2020, 26, 3104-3109.	3.2	66
228	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus Assessment by a German Group of Experts. <i>Breast Care</i> , 2020, 15, 82-95.	0.8	25
229	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	5.7	309
230	Fluorine-containing drugs approved by the FDA in 2019. <i>Chinese Chemical Letters</i> , 2020, 31, 2401-2413.	4.8	153
231	MRI-based radiogenomics analysis for predicting genetic alterations in oncogenic signalling pathways in invasive breast carcinoma. <i>Clinical Radiology</i> , 2020, 75, 561.e1-561.e11.	0.5	11

#	ARTICLE	IF	CITATIONS
232	PI3K inhibitors in thrombosis and cardiovascular disease. <i>Clinical and Translational Medicine</i> , 2020, 9, 8.	1.7	55
233	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
234	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Cancers</i> , 2020, 12, 617.	1.7	4
235	A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. <i>Scientific Reports</i> , 2020, 10, 4553.	1.6	35
236	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , 2020, 395, 817-827.	6.3	260
237	Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 10459.	1.6	32
238	Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1023.	1.3	22
239	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4579.	1.8	66
240	Dermatologic adverse events related to the PI3K $\hat{\pm}$ inhibitor alpelisib (BYL719) in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 227-237.	1.1	22
241	Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors?. <i>Future Oncology</i> , 2020, 16, 1851-1862.	1.1	4
243	Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4364.	1.8	4
244	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <i>Cancer Treatment Reviews</i> , 2020, 88, 102064.	3.4	41
245	Response of Brain Metastases From <i>PIK3CA</i> -Mutant Breast Cancer to Alpelisib. <i>JCO Precision Oncology</i> , 2020, 4, 572-578.	1.5	31
246	PDGFR $\hat{2}$ plays an essential role in patient vitreous-stimulated contraction of retinal pigment epithelial cells from epiretinal membranes. <i>Experimental Eye Research</i> , 2020, 197, 108116.	1.2	9
247	Advances in Care of the Breast Cancer Patient. <i>Seminars in Oncology</i> , 2020, 47, 176.	0.8	0
248	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4777-4784.	3.2	31
249	ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 588-600.	0.8	1
250	Precision medicine for ovarian clear cell carcinoma based on gene alterations. <i>International Journal of Clinical Oncology</i> , 2020, 25, 419-424.	1.0	12

#	ARTICLE	IF	CITATIONS
251	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 7-22.	0.4	5
252	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. <i>Nature Medicine</i> , 2020, 26, 181-187.	15.2	158
253	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. <i>Journal of Translational Medicine</i> , 2020, 18, 99.	1.8	12
254	Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups. <i>Scientific Reports</i> , 2020, 10, 2914.	1.6	18
255	Novel breast cancer treatment leads to hyperglycaemia. <i>Diabetic Medicine</i> , 2020, 37, 893-894.	1.2	2
256	Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment. <i>Cancers</i> , 2020, 12, 525.	1.7	27
257	Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis. <i>Modern Pathology</i> , 2020, 33, 1518-1526.	2.9	16
258	Insulinâ€“PI3K signalling: an evolutionarily insulated metabolic driver of cancer. <i>Nature Reviews Endocrinology</i> , 2020, 16, 276-283.	4.3	155
259	Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118679.	1.9	14
260	Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 377-386.	0.6	173
261	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2â” advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. <i>Breast</i> , 2020, 50, 64-70.	0.9	12
262	Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy. <i>Journal of Neuro-Oncology</i> , 2020, 147, 25-35.	1.4	11
263	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020, 9, 442.	1.8	7
264	Flawed trials for cancer. <i>Annals of Oncology</i> , 2020, 31, 331-333.	0.6	5
265	Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2â€“Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. <i>Clinical Breast Cancer</i> , 2020, 20, e439-e449.	1.1	10
266	Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1364-1377.	1.2	1
267	&lt;p&gt;Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options&lt;p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 675-686.	0.9	27
268	Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group. <i>Cancer Genetics</i> , 2020, 244, 11-20.	0.2	4

#	ARTICLE	IF	CITATIONS
269	Immunological characterization of HM5023507, an orally active PI3K $\hat{I}$ $\beta$ inhibitor. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00559.	1.1	4
271	PIK3CA mutations and specific treatment: do not forget lessons from RAS mutations and EGFR targeting. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 473-474.	1.1	4
272	Novel roles of phosphoinositides in signaling, lipid transport, and disease. <i>Current Opinion in Cell Biology</i> , 2020, 63, 57-67.	2.6	115
273	MAG11, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 223.	1.7	15
274	Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. <i>Apmsis</i> , 2020, 128, 298-307.	0.9	7
275	Molecular Classification of Gastric Cancer among Alaska Native People. <i>Cancers</i> , 2020, 12, 198.	1.7	18
276	Characteristics and Outcome of <i>AKT1</i> E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. <i>Cancer Discovery</i> , 2020, 10, 526-535.	7.7	36
277	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 345-357.	5.1	138
278	Capivasertib inhibits a key pathway in metastatic breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 318-319.	5.1	2
279	Comparison of methods for the isolation of cell-free DNA from cell culture supernatant. <i>Tumor Biology</i> , 2020, 42, 101042832091631.	0.8	30
280	Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor $\hat{E}$ positive, HER2 $\hat{E}$ negative advanced breast cancer molecularly stratified for <i>PIK3CA</i> mutations and loss of PTEN expression. <i>Cancer Medicine</i> , 2020, 9, 4527-4539.	1.3	7
281	PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 51.	1.3	27
282	Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 517-528.	1.5	60
283	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232
285	Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 233-248.	1.1	19
286	Molecular profiling in breast cancer $\hat{E}$ ready for clinical routine?. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 445-449.	0.3	7
287	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients $\hat{E}$ Part II: Metastatic Disease. <i>Drugs and Aging</i> , 2020, 37, 349-358.	1.3	3
288	Overcoming Endocrine Resistance in Breast Cancer. <i>Cancer Cell</i> , 2020, 37, 496-513.	7.7	411



#	ARTICLE	IF	CITATIONS
289	Theranostic Advances in Vascular Malformations. <i>Journal of Investigative Dermatology</i> , 2020, 140, 756-763.	0.3	41
290	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	5.7	96
291	Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1009-1024.	1.4	23
292	Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 445.	1.6	30
293	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	3.2	54
294	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020, 12, 1009.	1.7	123
295	Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 391-398.	0.8	12
296	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , 2020, 22, 33.	2.2	26
297	Breast Cancer: 45 Years of Research and Progress. <i>Journal of Clinical Oncology</i> , 2020, 38, 2454-2462.	0.8	15
298	Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA. <i>Future Oncology</i> , 2020, 16, 849-858.	1.1	9
299	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. <i>Cancers</i> , 2020, 12, 848.	1.7	14
300	The type of KRAS mutation drives PI3K signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101473.	0.7	9
301	<sup>18</sup> F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2 <sup>-</sup> Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 184-190.	2.8	20
302	An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 135-144.	0.9	5
303	Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?. <i>Clinical Cancer Research</i> , 2021, 27, 371-373.	3.2	9
304	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	2.9	14
305	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 447-459.	3.2	22
306	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 408-417.	3.2	21

#	ARTICLE	IF	CITATIONS
307	Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. <i>Modern Pathology</i> , 2021, 34, 983-993.	2.9	11
308	Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 81-92.	1.1	6
309	Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115890.	1.4	12
310	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 728-735.	2.9	64
311	Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. <i>Annals of Oncology</i> , 2021, 32, 208-217.	0.6	279
312	Updates on the treatment of invasive breast cancer: Quo Vadimus?. <i>Maturitas</i> , 2021, 145, 64-72.	1.0	7
313	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	49
314	The complex balance of PI3K inhibition. <i>Annals of Oncology</i> , 2021, 32, 127-128.	0.6	4
315	A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 139-152.	1.5	5
316	NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 1331-1345.	0.8	11
317	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103191.	2.0	9
318	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136.	3.4	25
319	Clinical utility of circulating tumor cells: an update. <i>Molecular Oncology</i> , 2021, 15, 1647-1666.	2.1	101
320	Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2 <sup>-</sup> ) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials. <i>Frontiers of Medicine</i> , 2021, 15, 208-220.	1.5	8
321	Triple-negative breast cancer: promising prognostic biomarkers currently in development. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 135-148.	1.1	80
322	Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA). <i>Breast Cancer Research and Treatment</i> , 2021, 185, 639-646.	1.1	2
323	Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. <i>Advances in Therapy</i> , 2021, 38, 109-136.	1.3	23
324	Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e150-e153.	1.1	7

#	ARTICLE	IF	CITATIONS
325	Palladium catalyzed C-C and C-N bond forming reactions: an update on the synthesis of pharmaceuticals from 2015-2020. <i>Organic Chemistry Frontiers</i> , 2021, 8, 384-414.	2.3	97
326	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 176-190.	157.7	101
327	Phase III randomized study of taselelisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. <i>Annals of Oncology</i> , 2021, 32, 197-207.	0.6	94
328	The role and therapeutic implications of PI3K signaling pathway in cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 39-41.	0.8	6
329	Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. <i>Cancer</i> , 2021, 127, 1293-1300.	2.0	19
330	SOLAR1s: alpelisib returns to earth?. <i>Annals of Oncology</i> , 2021, 32, 129-132.	0.6	2
331	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1105-1118.	3.2	24
332	Alpelisib in the treatment of metastatic HR+ breast cancer with <i>PIK3CA</i> mutations. <i>Future Oncology</i> , 2021, 17, 13-36.	1.1	9
333	Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier. <i>Clinical Breast Cancer</i> , 2021, 21, 120-127.	1.1	2
334	Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 93-106.	1.1	9
335	Triplet Therapy with Palbociclib, Taselelisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselelisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , 2021, 11, 92-107.	7.7	36
336	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 418-428.	3.2	16
337	Next-generation assessment of human epidermal growth factor receptor 2 gene ( <i>ERBB2</i> ) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. <i>Histopathology</i> , 2021, 78, 498-507.	1.6	7
338	Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells. <i>Breast Cancer</i> , 2021, 28, 206-215.	1.3	22
339	Targetable alterations in invasive pleomorphic lobular carcinoma of the breast. <i>Breast Cancer Research</i> , 2021, 23, 7.	2.2	7
340	Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22.		2
341	First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center. <i>Breast Care</i> , 2021, 16, 129-134.	0.8	3
342	Systemic Therapy for the Treatment of Breast Cancer. , 2021, , 81-87.		0

#	ARTICLE	IF	CITATIONS
343	Endolysosomal Disorders Affecting the Proximal Tubule of the Kidney: New Mechanistic Insights and Therapeutics. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2021, , 233-257.	0.9	2
344	In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors. <i>Cancers</i> , 2021, 13, 368.	1.7	8
345	Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients. <i>Cells</i> , 2021, 10, 212.	1.8	24
346	Multiple mutations within individual oncogenes. <i>Cancer Science</i> , 2021, 112, 483-489.	1.7	10
347	The immunomodulatory effects of endocrine therapy in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 19.	3.5	36
348	Clinical and neuroimaging findings in 33 patients with <sc>MCAP</sc> syndrome: A survey to evaluate relevant endpoints for future clinical trials. <i>Clinical Genetics</i> , 2021, 99, 650-661.	1.0	12
349	Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study. <i>JMIR Cancer</i> , 2021, 7, e27073.	0.9	3
350	Lobular Breast Cancer: A Review. <i>Frontiers in Oncology</i> , 2020, 10, 591399.	1.3	46
351	Liquid biopsy enters the clinic – implementation issues and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 297-312.	12.5	609
352	Isochromanoidenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation. <i>International Journal of Biological Sciences</i> , 2021, 17, 986-994.	2.6	2
353	Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. <i>Breast Care</i> , 2021, 16, 115-128.	0.8	10
354	Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542110322.	0.8	17
355	The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 443-449.	1.0	24
356	PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 67-75.	1.0	7
357	Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2560-2570.	3.2	37
358	Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Biological Sciences</i> , 2021, 17, 1104-1118.	2.6	13
359	CDK4/6 inhibitor plus endocrine therapy for hormone receptor–positive, HER2–negative metastatic breast cancer: The new standard of care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 3-14.	0.7	11
360	The evolution and advances of biomarker use in clinical trials for breast cancer treatment – a narrative review. <i>Translational Breast Cancer Research</i> , 0, 2, 6-6.	0.4	0

#	ARTICLE	IF	CITATIONS
361	Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. <i>Breast Cancer Research</i> , 2021, 23, 14.	2.2	15
362	CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. <i>Cancers</i> , 2021, 13, 332.	1.7	35
363	Breast and Gynecologic Tumors. , 2021, , 89-120.		0
364	Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). <i>JCO Precision Oncology</i> , 2021, 5, 215-226.	1.5	22
365	Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. <i>International Journal of Oncology</i> , 2021, 58, 211-225.	1.4	16
366	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	3.2	10
367	PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing. <i>Breast Cancer</i> , 2021, 28, 644-652.	1.3	8
368	ASCO 2020: highlights in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 58-61.	0.3	8
369	Targeted Neoadjuvant Therapies in HR+/HER2 <sup>-</sup> Breast Cancers: Challenges for Improving pCR. <i>Cancers</i> , 2021, 13, 458.	1.7	6
370	Clinical application of liquid biopsies to detect somatic <i>BRCA1/2</i> mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. <i>Oncotarget</i> , 2021, 12, 63-65.	0.8	1
371	Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	1.4	13
372	Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 101-107.	0.8	2
373	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 636.	1.8	29
374	Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. <i>Cancers</i> , 2021, 13, 369.	1.7	35
375	<i>PIK3CA</i> mutation detected by liquid biopsy in patients with metastatic breast cancer. <i>Journal of Nippon Medical School</i> , 2021, , .	0.3	5
376	Clinical implications of genomic alterations in metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 310-322.	2.0	12
377	Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples. <i>BMC Cancer</i> , 2021, 21, 114.	1.1	6
378	Drug-induced peripheral oedema: An aetiology-based review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3043-3055.	1.1	25

#	ARTICLE	IF	CITATIONS
379	Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression. <i>Frontiers in Immunology</i> , 2021, 12, 610149.	2.2	5
380	Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up. <i>European Journal of Cancer Care</i> , 2021, 30, e13429.	0.7	8
381	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 26.	2.2	19
382	Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-triazoles and 1-(Diarylmethyl)-1H-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 169.	1.7	5
383	Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3896-3904.	3.2	36
384	Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer. <i>Cancers</i> , 2021, 13, 926.	1.7	5
385	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. <i>Genes</i> , 2021, 12, 285.	1.0	18
386	Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms. <i>Cell Reports</i> , 2021, 34, 108750.	2.9	68
387	Targeting SHIP1 and SHIP2 in Cancer. <i>Cancers</i> , 2021, 13, 890.	1.7	15
389	The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review. <i>Journal of Modern Oncology</i> , 2020, 22, 47-55.	0.1	1
390	Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses. <i>BMC Cancer</i> , 2021, 21, 199.	1.1	12
391	Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. <i>Modern Pathology</i> , 2021, 34, 1062-1073.	2.9	17
392	Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients. <i>European Journal of Cancer</i> , 2021, 144, 224-231.	1.3	12
393	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	7.7	16
394	Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art. <i>Cancers</i> , 2021, 13, 902.	1.7	6
395	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021, 23, 21.	2.2	22
397	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. <i>Frontiers in Genetics</i> , 2020, 11, 598118.	1.1	18
398	The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2-metastatic breast cancer treated with alpelisib. <i>Journal of Modern Oncology</i> , 2020, 22, 56-59.	0.1	6

#	ARTICLE	IF	CITATIONS
399	Alpelisib for the treatment of <i>PIK3CA</i> -mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 667-675.	0.9	7
400	Phosphorylation of the proline-rich domain of WAVE3 drives its oncogenic activity in breast cancer. Scientific Reports, 2021, 11, 3868.	1.6	7
402	Circulating Free DNA and Its Emerging Role in Autoimmune Diseases. Journal of Personalized Medicine, 2021, 11, 151.	1.1	27
403	Novel therapeutic strategies for patients with metastatic triple-negative breast cancer. Journal of Modern Oncology, 2020, 22, 60-65.	0.1	2
404	Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. International Journal of Molecular Sciences, 2021, 22, 2088.	1.8	10
405	Random Forest Modelling of High-Dimensional Mixed-Type Data for Breast Cancer Classification. Cancers, 2021, 13, 991.	1.7	21
406	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hypersampled, Left-sided Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2505-2514.	3.2	14
407	Clinical application of circulating tumor DNA in breast cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1431-1442.	1.2	5
408	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1458.	1.7	17
409	Development of the CK1B-resistant HER2-positive breast cancer cell line and xenograft animal models. Cancer Medicine, 2021, 10, 2370-2379.	1.3	0
410	Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer. Scientific Reports, 2021, 11, 5566.	1.6	5
412	Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. Therapeutics and Clinical Risk Management, 2021, Volume 17, 193-207.	0.9	34
413	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 644737.	1.3	70
414	Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers, 2021, 13, 1538.	1.7	37
415	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. European Journal of Clinical Investigation, 2021, 51, e13535.	1.7	14
416	Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer, 2021, 21, 238.	1.1	31
417	PCGF3 promotes the proliferation and migration of non-small cell lung cancer cells via the PI3K/AKT signaling pathway. Experimental Cell Research, 2021, 400, 112496.	1.2	7
418	PIK3CA Mutation Assessment in HR+/HER2- Metastatic Breast Cancer: Overview for Oncology Clinical Practice. Journal of Molecular Pathology, 2021, 2, 42-54.	0.5	9

#	ARTICLE	IF	CITATIONS
419	PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3464.	1.8	119
420	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K± Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.4	20
421	Marcadores moleculares en el c�ncer de mama. Implicaciones terap�uticas. <i>Medicine</i> , 2021, 13, 1543-1545.	0.0	0
422	Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 77-89.	1.1	7
423	The Utility of Next-Generation Sequencing in Advanced Breast and Gynecologic Cancers. <i>American Journal of Clinical Pathology</i> , 2021, 156, 455-460.	0.4	3
424	Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	8
425	PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. <i>Annals of Translational Medicine</i> , 2021, 9, 410-410.	0.7	37
426	Breast cancer liver metastasis: current and future treatment approaches. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 263-277.	1.7	42
427	Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature. <i>AACE Clinical Case Reports</i> , 2021, 7, 127-131.	0.4	18
428	NODAL/TGF�2 signalling mediates the self-sustained stemness induced by <i>PIK3CAH1047R</i> homozygosity in pluripotent stem cells. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	5
429	Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer ��PanHER��. <i>Cancers</i> , 2021, 13, 1225.	1.7	8
430	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. <i>Cells</i> , 2021, 10, 659.	1.8	77
431	The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 595675.	1.3	4
432	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	1.7	5
433	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021, 39, 1366-1374.	1.2	17
434	Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix. <i>Cancers</i> , 2021, 13, 1215.	1.7	13
435	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor��Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	3.2	4
436	Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs. <i>Nature Communications</i> , 2021, 12, 1850.	5.8	68



#	ARTICLE	IF	CITATIONS
437	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 430-438.	0.3	14
438	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 454-467.	12.5	11
439	The Way of the Future: Personalizing Treatment Plans Through Technology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 12-23.	1.8	8
440	Organismal roles for the PI3K $\alpha$ and $\beta$ isoforms: their specificity, redundancy or cooperation is context-dependent. <i>Biochemical Journal</i> , 2021, 478, 1199-1225.	1.7	12
441	Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 628690.	1.6	165
442	Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2 $\alpha$ Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). <i>Clinical Cancer Research</i> , 2021, 27, 4177-4185.	3.2	47
443	Disease-related mutations in PI3K $\beta$ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. <i>ELife</i> , 2021, 10, .	2.8	28
444	Breast Cancer Brain Metastasis – Overview of Disease State, Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 1078.	1.7	41
445	Clinical cancer genomic profiling. <i>Nature Reviews Genetics</i> , 2021, 22, 483-501.	7.7	79
446	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. <i>Nature Communications</i> , 2021, 12, 1780.	5.8	39
447	Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. <i>Diagnostics</i> , 2021, 11, 733.	1.3	13
451	Cardiovascular toxicity of breast cancer treatment: an update. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 15-24.	1.1	7
452	Next-Generation Endocrine Therapies for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1383-1388.	0.8	19
453	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. <i>Lancet Oncology</i> , The, 2021, 22, 489-498.	5.1	157
454	The Epigenetic landscape of Circulating tumour cells. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188514.	3.3	16
456	Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126.	0.7	0
457	Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3275-3277.	3.2	0
458	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 676-686.	1.5	20

#	ARTICLE	IF	CITATIONS
459	A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 1811.	1.7	6
460	The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. <i>Scientific Reports</i> , 2021, 11, 9091.	1.6	20
461	Routine Molecular Pathology Diagnostics in Precision Oncology. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2021, 118, .	0.6	2
462	Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors. <i>Journal of Personalized Medicine</i> , 2021, 11, 360.	1.1	3
463	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	5.8	54
464	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	2.0	19
465	Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 881-888.	0.8	4
466	The importance of Ras in drug resistance in cancer. <i>British Journal of Pharmacology</i> , 2022, 179, 2844-2867.	2.7	26
467	The emerging relationship between metabolism and DNA repair. <i>Cell Cycle</i> , 2021, 20, 943-959.	1.3	12
468	Targeting rare and non-canonical driver variants in NSCLC â€“ An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	0.9	8
469	Update Breast Cancer 2020 Part 5 â€“ Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 469-480.	0.8	6
470	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021, 11, 874-899.	7.7	107
471	Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. <i>JCO Global Oncology</i> , 2021, 7, 474-485.	0.8	2
472	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. <i>Npj Breast Cancer</i> , 2021, 7, 41.	2.3	33
473	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. <i>Cancers</i> , 2021, 13, 1861.	1.7	4
474	Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women. <i>Aging</i> , 2021, 13, 11860-11876.	1.4	7
475	Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers. <i>Frontiers in Pharmacology</i> , 2021, 12, 631135.	1.6	2
477	Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study. <i>Annals of Oncology</i> , 2021, 32, 427-430.	0.6	1

#	ARTICLE	IF	CITATIONS
478	Alpelisib-Induced Diabetic Ketoacidosis. <i>Cureus</i> , 2021, 13, e14796.	0.2	10
479	Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case Report. <i>JCO Precision Oncology</i> , 2021, 5, 744-750.	1.5	10
480	The emerging role of RNA N6-methyladenosine methylation in breast cancer. <i>Biomarker Research</i> , 2021, 9, 39.	2.8	22
481	Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 877-892.	2.4	27
482	Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, PIK3CA–Mutated Breast Cancer. <i>Oncologist</i> , 2021, 26, e1133-e1142.	1.9	17
483	INPP4B promotes PI3K–dependent late endosome formation and Wnt/–catenin signaling in breast cancer. <i>Nature Communications</i> , 2021, 12, 3140.	5.8	30
484	Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy. <i>Scientific Reports</i> , 2021, 11, 10567.	1.6	7
485	Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant. <i>Breast Cancer Research</i> , 2021, 23, 57.	2.2	7
486	Mast Cells: A New Frontier for Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1270.	1.8	59
487	IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 2250.	1.7	8
488	Entropy-driven strand displacement reaction for ultrasensitive detection of circulating tumor DNA based on upconversion and Fe <sub>3</sub> O <sub>4</sub> nanocrystals. <i>Science China Materials</i> , 2021, 64, 2593-2600.	3.5	6
489	Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1803-1822.	0.9	24
490	Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive. <i>Pharmaceuticals</i> , 2021, 14, 455.	1.7	18
491	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	3.6	26
492	Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 85.	3.6	21
493	Breast cancer. <i>Lancet, The</i> , 2021, 397, 1750-1769.	6.3	731
494	Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL. <i>Journal of Clinical Oncology</i> , 2021, 39, 1671-1673.	0.8	0
495	The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 648663.	1.6	23

#	ARTICLE	IF	CITATIONS
496	Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 943-952.	1.5	23
498	Pancreatic cancer intrinsic PI3K activity accelerates metastasis and rewires macrophage component. <i>EMBO Molecular Medicine</i> , 2021, 13, e13502.	3.3	19
499	Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts. <i>Molecular Imaging</i> , 2021, 2021, 1-14.	0.7	3
501	A Phase I Study of Alpelisib in Combination with Trastuzumab and UJM716 in Patients with PI3KCA-Mutated HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3867-3875.	3.2	15
502	Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations. <i>Frontiers in Oncology</i> , 2021, 11, 640490.	1.3	17
503	Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2929-2939.	1.0	3
504	Optimal integration of CDK4/6 inhibitors for treatment of hormone receptor-positive metastatic breast cancer. <i>Practical Oncology</i> , 2021, 4, 11-18.	0.1	0
505	Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors. <i>Breast Care</i> , 2022, 17, 1-8.	0.8	2
506	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	0.8	7
507	Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma. <i>Viruses</i> , 2021, 13, 910.	1.5	12
508	Precision Oncology. <i>Advances in Oncology</i> , 2021, 1, 97-112.	0.1	0
509	The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 780-788.	2.9	10
510	Kinase drug discovery 20 years after imatinib: progress and future directions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 551-569.	21.5	497
511	Observations with alpelisib in older patients (≥65 year of age) with breast cancer in a non-clinical trial setting. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 15-20.	1.1	4
512	The present and future of PI3K inhibitors for cancer therapy. <i>Nature Cancer</i> , 2021, 2, 587-597.	5.7	63
513	Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 613.	1.1	2
514	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. <i>Breast</i> , 2021, 57, 104-112.	0.9	14
515	Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies. <i>Circulation Research</i> , 2021, 129, 136-154.	2.0	88

#	ARTICLE	IF	CITATIONS
516	PI3K inhibitors are finally coming of age. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 741-769.	21.5	222
517	Diabète induit par l'ampelisib: À propos d'un cas. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 398-401.	1.1	1
518	Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e000082.	1.6	55
519	PI3K functions as a hub in mechanotransduction. <i>Trends in Biochemical Sciences</i> , 2021, 46, 878-888.	3.7	20
520	Oligometastatic Breast Cancer: How to Manage It?. <i>Journal of Personalized Medicine</i> , 2021, 11, 532.	1.1	8
521	IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. <i>Annals of Oncology</i> , 2021, 32, 736-745.	0.6	23
522	Molecular Characterization of Muellierian Tumors of the Urinary Tract. <i>Genes</i> , 2021, 12, 880.	1.0	5
523	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. <i>Oncologist</i> , 2021, 26, 835-844.	1.9	16
524	Detection of actionable mutations in archived cytological bile specimens. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 837-847.	1.4	8
525	USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor. <i>Cell Death and Disease</i> , 2021, 12, 619.	2.7	13
526	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. <i>Breast</i> , 2021, 57, 86-94.	0.9	6
527	Post San Antonio update - my top three abstracts!. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 244-246.	0.3	1
528	Metabolic Reprogramming and Molecular Rewiring in Cancer: Therapeutic Opportunities. <i>Indonesian Biomedical Journal</i> , 2021, 13, 114-39.	0.2	3
529	NGS in Lung, Breast, and Unknown Primary Cancer in Colombia: A Multidisciplinary Consensus on Challenges and Opportunities. <i>JCO Global Oncology</i> , 2021, 7, 1012-1023.	0.8	7
531	Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 72.	2.3	15
532	Locally Advanced Primary Small Cell Carcinoma of the Breast: A Case Report and Review of Current Evidence. <i>Case Reports in Oncology</i> , 2021, 14, 761-766.	0.3	6
533	Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR + PIK3CA Mutated Advanced Breast Cancer. <i>Oncologist</i> , 2021, 26, S11-S12.	1.9	1
534	Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas. <i>Frontiers in Oncology</i> , 2021, 11, 670275.	1.3	4

#	ARTICLE	IF	CITATIONS
535	Patient-Reported Outcomes in Patients With <i>PIK3CA</i> -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 2005-2015.	0.8	23
536	PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103334.	2.0	20
537	A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 1-9.	1.1	6
538	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
539	Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer. <i>Cancer Cell International</i> , 2021, 21, 306.	1.8	4
540	A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia. <i>Current Problems in Cancer</i> , 2022, 46, 100776.	1.0	7
541	The Opportunities and Challenges of Molecular Tagging Next-Generation Sequencing in Liquid Biopsy. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 537-547.	1.6	3
543	Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. <i>Nature Cancer</i> , 2021, 2, 680-692.	5.7	56
544	Risk Signature of Cancer-Associated Fibroblast-Secreted Cytokines Associates With Clinical Outcomes of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 628677.	1.3	9
545	The molecular tumor burden index as a response evaluation criterion in breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 251.	7.1	19
546	Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5012-5019.	3.2	10
547	The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. <i>Neuro-Oncology</i> , 2022, 24, 213-225.	0.6	36
548	ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. <i>Cells</i> , 2021, 10, 1659.	1.8	16
549	Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR. <i>Biomedicines</i> , 2021, 9, 906.	1.4	30
550	Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications. <i>Cancers</i> , 2021, 13, 3460.	1.7	15
551	AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. <i>Cancer Discovery</i> , 2021, 11, 3064-3089.	7.7	32
552	Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor. <i>Animals</i> , 2021, 11, 2079.	1.0	6
553	3q26 Amplifications in Cervical Squamous Carcinomas. <i>Current Oncology</i> , 2021, 28, 2868-2880.	0.9	4

#	ARTICLE	IF	CITATIONS
554	SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report. <i>Clinical Diabetes and Endocrinology</i> , 2021, 7, 17.	1.3	10
555	Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 681530.	1.3	15
556	Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258.	0.8	4
557	“Single-subject studies”-derived analyses unveil altered biomechanisms between very small cohorts: implications for rare diseases. <i>Bioinformatics</i> , 2021, 37, i67-i75.	1.8	2
558	Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3K Inhibitor Resistance Mechanisms and Drug Combinations. <i>Cancer Research</i> , 2021, 81, 4603-4617.	0.4	13
559	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 563-576.	1.6	5
560	Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223.	3.4	34
561	Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3959-3977.	0.8	121
562	Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. <i>Cancers</i> , 2021, 13, 3517.	1.7	68
563	A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	20
565	Pharmacological and cell-specific genetic PI3K inhibition worsens cardiac remodeling after myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 157, 17-30.	0.9	9
567	Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics. <i>JCO Precision Oncology</i> , 2021, 5, 1297-1311.	1.5	9
568	Molecular Testing in Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1422-1432.	1.2	14
569	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	0.9	1
570	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. <i>Nature Communications</i> , 2021, 12, 5112.	5.8	38
571	Hormonoterapia en c�ncer de mama metast�sico. Revisi�n de la Evidencia y Abordaje Terap�utico en el Instituto Nacional de Cancerolog�a, Bogot� - Colombia. <i>Revista Colombiana De Cancerolog�a</i> , 0, 25, 142-151.	0.0	0
572	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003732.	3.9	38
573	Breast Cancer Treatments: Updates and New Challenges. <i>Journal of Personalized Medicine</i> , 2021, 11, 808.	1.1	108

#	ARTICLE	IF	CITATIONS
575	Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer. <i>Cancer Gene Therapy</i> , 2022, 29, 859-869.	2.2	11
576	An update of new small-molecule anticancer drugs approved from 2015 to 2020. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113473.	2.6	27
577	Cardio-Oncology. <i>JACC Basic To Translational Science</i> , 2021, 6, 705-718.	1.9	21
578	ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing. <i>Translational Oncology</i> , 2021, 14, 101132.	1.7	0
579	Anticancer potential of novel $\beta$ -lactam derivatives targeting the PI3K/AKT signaling pathway. <i>Biochemical Pharmacology</i> , 2021, 190, 114659.	2.0	8
580	Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting. <i>BMC Proceedings</i> , 2021, 15, 15.	1.8	5
581	Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study. <i>Genetics in Medicine</i> , 2021, 23, 2433-2442.	1.1	12
582	Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. <i>Nature Communications</i> , 2021, 12, 5053.	5.8	14
583	Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 949-957.	1.0	10
584	Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect. <i>Frontiers in Oncology</i> , 2021, 11, 726785.	1.3	5
585	The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e16919.	0.2	2
586	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- $\gamma$ and $\delta$ . <i>Frontiers in Immunology</i> , 2021, 12, 718621.	2.2	16
587	Open questions and controversies in the systemic treatment of breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 591-596.	1.1	1
589	Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 17316.	1.6	18
590	Identification of putative actionable alterations in clinically relevant genes in breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1270-1284.	2.9	1
591	Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis. <i>ESMO Open</i> , 2021, 6, 100187.	2.0	2
592	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5760-5770.	3.2	25
593	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	2.0	15



#	ARTICLE	IF	CITATIONS
594	Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 127.	6.9	12
595	Pan-Cancer Molecular Biomarkers. <i>Surgical Pathology Clinics</i> , 2021, 14, 507-516.	0.7	4
596	Reply to S. Cavalieri et al. <i>JCO Precision Oncology</i> , 2021, 5, 1528-1529.	1.5	0
597	Treatment strategies for mosaic overgrowth syndromes of the PI3K-AKT-mTOR pathway. <i>British Medical Bulletin</i> , 2021, 140, 36-49.	2.7	4
598	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 213-226.	1.1	2
599	Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 227-240.	1.1	2
600	TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer. <i>Scientific Reports</i> , 2021, 11, 19261.	1.6	14
601	Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers. <i>American Journal of Clinical Pathology</i> , 2021, , .	0.4	0
602	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	2.9	14
603	Breast cancer immunotherapy: Current biomarkers and the potential of in vitro assays. <i>Current Opinion in Biomedical Engineering</i> , 2022, 21, 100348.	1.8	2
605	Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas. <i>Cancers</i> , 2021, 13, 4810.	1.7	5
606	Landscape Analysis of Breast Cancer and Acute Myeloid Leukemia Trials Using the My Cancer Genome Clinical Trial Data Model. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 975-984.	1.0	1
607	Molecular Pathology of Breast Tumors. <i>Surgical Pathology Clinics</i> , 2021, 14, 455-471.	0.7	2
608	Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1356-1364.	2.9	3
609	A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. <i>Breast Cancer Management</i> , 2021, 10, BMT59.	0.2	2
610	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6115-6123.	3.2	9
611	A late endosome signaling hub that couples PI3K and WNT/β-catenin signaling in breast cancer. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1954470.	0.3	0
612	Alpelisib-induced hyperglycemia in older patients with breast Cancer: Qualitative findings. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1114-1117.	0.5	4

#	ARTICLE	IF	CITATIONS
613	Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1493-1506.	1.5	4
614	Management of hormone receptorâ€“positive, human epidermal growth factor 2â€“negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 189-201.	1.1	10
615	Knockout of Calcyclin Binding Protein Impedes the Growth of Breast Cancer Cells by Regulating Cell Apoptosis and Î²-Catenin Signaling. <i>DNA and Cell Biology</i> , 2021, 40, 1317-1324.	0.9	2
616	Somatic <i>PIK3CA</i> Mutations in Sporadic Cerebral Cavernous Malformations. <i>New England Journal of Medicine</i> , 2021, 385, 996-1004.	13.9	53
617	A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2851-2854.	0.8	0
618	The Landscape of <i>PIK3CA</i> Mutations in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 201-215.	1.0	24
619	Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. <i>Npj Precision Oncology</i> , 2021, 5, 85.	2.3	1
620	Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 241-253.	1.1	8
621	6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapies. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 6, 111-117.	0.0	0
622	Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis. <i>Cancers</i> , 2021, 13, 4816.	1.7	25
624	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	1.7	7
625	Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. <i>Clinical Breast Cancer</i> , 2021, 21, 509-520.	1.1	13
626	Combined endocrine and targeted therapy in luminal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1237-1251.	1.1	12
627	Phosphoproteomics Identifies <i>PI3K</i> Inhibitorâ€“selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2433-2445.	1.9	3
628	Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. <i>Breast</i> , 2021, 59, 294-300.	0.9	12
629	Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 50, 128335.	1.0	7
630	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
631	Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14603-14619.	2.9	6

#	ARTICLE	IF	CITATIONS
632	Low-dose mono(2-ethylhexyl) phthalate promotes ovarian cancer development through PPAR $\alpha$ -dependent PI3K/Akt/NF- $\kappa$ B pathway. <i>Science of the Total Environment</i> , 2021, 790, 147990.	3.9	24
633	PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. <i>ESMO Open</i> , 2021, 6, 100230.	2.0	15
634	Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. <i>European Journal of Cancer</i> , 2021, 157, 40-49.	1.3	3
635	FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188595.	3.3	13
636	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
637	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 228-235.	0.8	20
638	Mutant SF3B1 promotes AKT- and NF- $\kappa$ B-driven mammary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	22
639	The genomic landscape of breast cancer brain metastases: a systematic review. <i>Lancet Oncology</i> , The, 2021, 22, e7-e17.	5.1	57
640	Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America. <i>Journal of Molecular Medicine</i> , 2021, 99, 311-313.	1.7	17
641	Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics. <i>Journal of Cancer</i> , 2021, 12, 4408-4417.	1.2	16
643	Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors. <i>Molecular Biology Reports</i> , 2021, 48, 915-925.	1.0	20
644	Saying goodbye to primary endocrine resistance for advanced breast cancer?. <i>Medical Oncology</i> , 2021, 38, 5.	1.2	3
645	Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. <i>Cancer Biology and Therapy</i> , 2021, 22, 89-105.	1.5	15
646	Molecular profiling of soft-tissue sarcomas with FoundationOne <sup>®</sup> Heme identifies potential targets for sarcoma therapy: a single-centre experience. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110291.	1.4	3
647	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342199585.	0.6	22
648	A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100457.	0.7	5
649	PIK3CA Mutations in Uterine Cervix Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 220.	1.0	11
650	Proteogenomic approach to drug targets in osteosarcomas with different original sites. <i>Journal of Electrophoresis</i> , 2021, 65, 1-11.	0.2	1

#	ARTICLE	IF	CITATIONS
651	Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age. JAMA Network Open, 2020, 3, e2028644.	2.8	9
652	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology, 2020, 151, 102978.	2.0	79
653	Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. Current Problems in Cancer, 2020, 44, 100606.	1.0	11
654	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	0.9	47
655	Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations. Human Pathology, 2020, 102, 94-103.	1.1	16
656	Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44. Biochemical Journal, 2019, 476, 3081-3107.	1.7	14
657	Small molecule targeting of SHIP1 and SHIP2. Biochemical Society Transactions, 2020, 48, 291-300.	1.6	21
658	Cardiovascular toxicity of PI3K inhibitors. Clinical Science, 2020, 134, 2595-2622.	1.8	11
659	Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study. South Asian Journal of Cancer, 2020, 9, 074-079.	0.2	6
660	Innovations in targeted therapies for triple negative breast cancer. Current Opinion in Obstetrics and Gynecology, 2021, 33, 34-47.	0.9	4
668	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open Cancer Horizons pro and con discussion. ESMO Open, 2019, 4, e000565.	2.0	8
669	Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis. BioMed Research International, 2020, 2020, 1-12.	0.9	7
670	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer. Clinical Cancer Research, 2020, 26, 6417-6428.	3.2	11
671	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 1361-1370.	3.2	25
672	Unbiased Detection of Driver Mutations in Extramammary Paget Disease. Clinical Cancer Research, 2021, 27, 1756-1765.	3.2	24
673	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating $\beta$ -Catenin Signaling. Molecular Cancer Research, 2021, 19, 573-584.	1.5	10
674	Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations. JCI Insight, 2019, 4, .	2.3	39
675	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 30-43.	1.8	107

#	ARTICLE	IF	CITATIONS
676	Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. PLoS Medicine, 2020, 17, e1003363.	3.9	18
677	The mutational landscape of the <scp>SCAN</scp> â€ real-world primary breast cancer transcriptome. EMBO Molecular Medicine, 2020, 12, e12118.	3.3	36
678	The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience. Endocrine-Related Cancer, 2020, 27, R307-R327.	1.6	23
679	Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. Oncotarget, 2020, 11, 3688-3697.	0.8	13
680	A systematic review and meta-analysis of selected toxicity endpoints of alpelisib. Oncotarget, 2020, 11, 3793-3799.	0.8	9
681	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. Annals of Translational Medicine, 2020, 8, 1603-1603.	0.7	8
682	The role of radiation therapy and systemic therapies in elderly with breast cancer. Translational Cancer Research, 2020, 9, S97-S109.	0.4	2
683	Evolution of Molecular Targets in Melanoma Treatment. Current Pharmaceutical Design, 2020, 26, 396-414.	0.9	10
684	Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance. Future Oncology, 2020, 16, 2863-2878.	1.1	2
685	Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. Annals of Breast Cancer and Therapy, 2020, 4, 48-57.	0.8	11
686	Major clinical research advances in gynecologic cancer in 2019. Journal of Gynecologic Oncology, 2020, 31, e48.	1.0	10
687	Triple-negative breast cancer therapy: Current and future perspectives (Review). International Journal of Oncology, 2020, 57, 1245-1261.	1.4	196
688	Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome. Cancer Research Statistics and Treatment, 2020, 3, 275.	0.1	5
689	Letrozole and Palbociclib in Advanced Breast Cancer: Outcome from Cancer Institute, Chennai. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 182-186.	0.1	2
690	Liquid Biopsy in Breast Cancer: A Focused Review. Archives of Pathology and Laboratory Medicine, 2021, 145, 678-686.	1.2	64
691	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478.	2.3	848
692	The Lipid Kinase PI3KÎ± is Required for the Cohesion and Survival of Cancer Cells Disseminated in Serous Cavities. SSRN Electronic Journal, 0, , .	0.4	0
693	A primer on harnessing non-enzymatic post-translational modifications for drug design. RSC Medicinal Chemistry, 2021, 12, 1797-1807.	1.7	1

#	ARTICLE	IF	CITATIONS
694	Updates in endocrine therapy for metastatic breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	6
695	Metastatic Breast Cancer. <i>UNIPA Springer Series</i> , 2021, , 467-479.	0.1	0
696	Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10931.	1.8	22
697	Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials. <i>Pharmaceutics</i> , 2021, 13, 1748.	2.0	38
698	Small Molecule Kinase Inhibitor Drugs (1995â€“2021): Medical Indication, Pharmacology, and Synthesis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1047-1131.	2.9	114
699	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. <i>Journal of Molecular Medicine</i> , 2021, 99, 1691-1710.	1.7	40
701	Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer. <i>Global Medical Genetics</i> , 2022, 09, 001-003.	0.4	0
702	Diverse landscape of dermatologic toxicities from smallâ€“molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	0.7	5
703	Harnessing multimodal data integration to advance precision oncology. <i>Nature Reviews Cancer</i> , 2022, 22, 114-126.	12.8	168
704	Drug target inference by mining transcriptional data using a novel graph convolutional network framework. <i>Protein and Cell</i> , 2022, 13, 281-301.	4.8	18
705	Cardiometabolic consequences of targeted anticancer therapies. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	3
706	Clinical Review on the Management of Hormone Receptorâ€“Positive Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 319-327.	1.4	40
707	Palbociclib as an early-line treatment for Japanese patients with hormone receptorâ€“positive/human epidermal growth factor receptor 2â€“negative advanced breast cancer: a review of clinical trial and real-world data. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2179-2193.	1.0	4
708	Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature. <i>Frontiers in Endocrinology</i> , 2021, 12, 659537.	1.5	1
709	Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology. <i>Biomedicines</i> , 2021, 9, 1500.	1.4	4
710	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. <i>Cancers</i> , 2021, 13, 5198.	1.7	10
711	A biomarker study in Peruvian males with breast cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 926-934.	0.9	1
712	Alpelisib administration reduced lymphatic malformations in a mouse model and in patients. <i>Science Translational Medicine</i> , 2021, 13, eabg0809.	5.8	34

#	ARTICLE	IF	CITATIONS
713	Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 920.	2.7	13
714	De novo metastatic breast cancer arising in young women: review of the current evidence. <i>Clinical Breast Cancer</i> , 2021, . .	1.1	6
715	Cell-free Nucleic Acids in Cancer. <i>Advances in Molecular Pathology</i> , 2021, 4, 187-198.	0.2	1
716	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021, 158, 169-180.	1.3	9
717	Liquid biopsy in metastatic breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 1062-1068.	0.9	1
722	Hormone Receptor-Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 275-279.	0.2	0
723	Case Report: Sustained Complete Response to PI3K Inhibition in a Patient with Metastatic Breast Cancer Harboring PIK3CA, NF1, and CDH1 Mutations. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 133-136.	0.6	0
724	The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	8
725	Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance. <i>Biomarkers in Medicine</i> , 2020, 14, 495-498.	0.6	3
726	Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Journal of Surgery and Medicine</i> , 0, . .	0.0	1
728	Breast Cancer in Patients 80 Years-Old and Older. <i>The Journal of Breast Health</i> , 2020, 16, 208-212.	0.4	13
729	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. <i>Oncotarget</i> , 2020, 11, 2172-2181.	0.8	5
730	Construction of SIRT1 gene shRNA lentivirus vector and its effect on the proliferation of breast cancer cells. <i>Cellular and Molecular Biology</i> , 2020, 66, 204-210.	0.3	0
732	Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA. <i>Oncology Research and Treatment</i> , 2022, 45, 4-11.	0.8	10
733	Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2 <sup>+</sup> Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. <i>Cancers</i> , 2021, 13, 5397.	1.7	7
734	U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. <i>Clinical Cancer Research</i> , 2022, 28, 1072-1086.	3.2	31
735	Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
736	Adverse events of targeted therapies approved for women's cancers. <i>International Journal of Women's Dermatology</i> , 2021, 7, 552-559.	1.1	0

#	ARTICLE	IF	CITATIONS
737	Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 757-774.	1.6	16
738	Estrogen Receptor: A Paradigm for Targeted Therapy. <i>Cancer Research</i> , 2021, 81, 5396-5398.	0.4	6
739	Molecular Basis of Breast Cancer. , 2022, , 3-15.		0
740	Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor- $\alpha$ -positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2022, 28, 821-830.	3.2	26
741	Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy. <i>Pediatric Dermatology</i> , 2021, 38, 18-30.	0.5	6
742	Integrated Molecular Profiling as an Approach to Identify PI3K Inhibitor Resistance Mechanisms. , 0, , .		0
743	Changing paradigms in breast cancer treatment. <i>European Journal of Translational and Clinical Medicine</i> , 2020, 3, 53-63.	0.0	2
746	Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene. <i>Meditinskiy Sovet</i> , 2020, , 40-46.	0.1	1
747	Microgravity: New aspect for breast cancer treatment, a review. <i>Acta Astronautica</i> , 2022, 190, 62-73.	1.7	5
750	Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis. <i>Journal of Breast Cancer</i> , 2020, 23, 460.	0.8	1
751	2018-2019 Drug Updates in Solid Tumors. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 255-258.	0.2	0
752	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1475-1495.	0.6	454
753	Cryo-EM structures of PI3K $\alpha$ reveal conformational changes during inhibition and activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	17
754	Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated PI3K $\alpha$ in early and advanced HER2 $\alpha$ -positive breast cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e589.	1.7	6
755	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. <i>Frontiers in Oncology</i> , 2021, 11, 744112.	1.3	3
756	Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient. <i>Cureus</i> , 2021, 13, e19295.	0.2	4
757	Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2022, 126, 456-463.	2.9	15
758	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11878.	1.8	1



#	ARTICLE	IF	CITATIONS
759	Targeting lysosomes in human disease: from basic research to clinical applications. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 379.	7.1	58
761	Practice-Changing Interventions in the Systemic Management of Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 941-944.	2.3	0
762	The role of PIK3CA mutations in the development of breast cancer (a literature review). <i>ZaporoÅ¼skij Medicinskij Å½urnal</i> , 2020, .	0.0	0
764	Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies. <i>PeerJ</i> , 2020, 8, e10069.	0.9	1
768	Prediction of PIK3CA mutations from cancer gene expression data. <i>PLoS ONE</i> , 2020, 15, e0241514.	1.1	5
769	KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival. <i>American Journal of Cancer Research</i> , 2020, 10, 897-907.	1.4	54
770	Somatic mutation profiling in -negative breast and ovarian cancer patients by multigene panel sequencing. <i>American Journal of Cancer Research</i> , 2020, 10, 2919-2932.	1.4	5
771	Alpelisib: A Novel Therapy for Patients With Mutated Metastatic Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 768-775.	0.2	3
772	Pinin promotes tumor progression via activating CREB through PI3K/AKT and ERK/MAPK pathway in prostate cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 1286-1303.	1.4	3
773	Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing. <i>American Journal of Cancer Research</i> , 2021, 11, 3240-3251.	1.4	0
774	A review of the endocrine resistance in hormone-positive breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 3813-3831.	1.4	3
775	Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor. <i>JAAD Case Reports</i> , 2022, 19, 25-27.	0.4	1
776	Mammakarzinom. , 2022, , 340-351.		0
777	Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer. <i>Cureus</i> , 2021, 13, e19441.	0.2	1
778	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
779	Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype. <i>PLoS Genetics</i> , 2021, 17, e1009876.	1.5	14
780	Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2180-2189.	1.1	6
781	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. <i>Cancer Discovery</i> , 2022, 12, 90-107.	7.7	124

#	ARTICLE	IF	CITATIONS
782	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. <i>Cancers</i> , 2021, 13, 5643.	1.7	16
783	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0
784	RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues. <i>Molecular Oncology</i> , 2022, 16, 1091-1118.	2.1	8
785	Targeted Therapy in HR+ HER2+ Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options. <i>Cancers</i> , 2021, 13, 5994.	1.7	11
786	Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide,φ Assay. <i>Clinical Breast Cancer</i> , 2022, 22, e457-e462.	1.1	6
787	A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer. <i>Annals of Oncology</i> , 2022, 33, 143-157.	0.6	28
788	Standard of Care in Hormone Receptor-Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?. <i>JCO Oncology Practice</i> , 2022, 18, 331-334.	1.4	4
789	Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 114-131.	12.5	76
790	Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 6004.	1.7	6
791	Characterization of Alpelisib in Rat Plasma by a Newly Developed UPLC-MS/MS Method: Application to a Drug-Drug Interaction Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 743411.	1.6	4
792	Diabetes and Cancer: Risk, Challenges, Management and Outcomes. <i>Cancers</i> , 2021, 13, 5735.	1.7	40
793	Pharmacogenomics in solid cancers and hematologic malignancies: improving personalized drug prescription. <i>Therapie</i> , 2021, , .	0.6	1
794	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. <i>JCO Precision Oncology</i> , 2021, 5, 1768-1776.	1.5	12
795	Development of novel agents for the treatment of early estrogen receptor positive breast cancer. <i>Breast</i> , 2022, 62, S34-S42.	0.9	8
796	<i>TP53</i> mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8581-8594.	1.3	14
798	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 565-576.	1.1	32
799	Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. <i>Clinical Cancer Research</i> , 2022, 28, 1107-1116.	3.2	7
800	A multidisciplinary approach to optimizing care of patients treated with alpelisib. <i>Breast</i> , 2022, 61, 156-167.	0.9	12

#	ARTICLE	IF	CITATIONS
801	Mammakarzinom: Update 2019. , 0, , .		0
802	Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 768-775.	0.2	8
804	Incidence, Characteristics, and Management of Alpelisib-Associated Rash in Patients With Advanced Breast Cancer. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s111.	0.1	1
806	Recent Advancements in the Development of Anti-Breast Cancer Synthetic Small Molecules. <i>Molecules</i> , 2021, 26, 7611.	1.7	5
807	Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. <i>Cell Reports</i> , 2022, 38, 110278.	2.9	14
809	Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations. <i>Frontiers in Endocrinology</i> , 2022, 13, 802612.	1.5	6
810	Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 303-311.	1.1	6
811	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 780379.	1.3	7
812	Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 99.	1.1	16
813	Spectrum of MAP3K1 mutations in breast cancer is luminal subtypeâ€predominant and related to prognosis. <i>Oncology Letters</i> , 2022, 23, 68.	0.8	5
814	Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463.		3
815	<i>PIK3CA</i> Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492110688.	0.6	4
816	Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups. <i>Gynecologic Oncology</i> , 2022, 164, 558-565.	0.6	9
817	Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Likeâ€Induced Protein Changes in Estrogen Receptorâ€Positive, Human Epidermal Growth Factor Receptor 2â€Negative Breast Cancer Throughout Disease Progression. <i>JCO Precision Oncology</i> , 2022, 6, e2100190.	1.5	5
818	Canine models of human cancer: Bridging the gap to improve precision medicine. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 67-99.	0.9	8
819	Updates on breast biomarkers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 163-176.	1.4	33
821	A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer. <i>Surgical Pathology Clinics</i> , 2022, 15, 105-120.	0.7	6
822	Eligibility Criteria Can Be Deceiving: How Direct and Indirect Exclusion Criteria Affects Recruitment of Under-Served Groups in Breast Cancer Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
823	Biomarkers of everolimus efficacy in breast cancer therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522110736.	0.5	2
824	The initial hormone receptor/HER2 subtype is the main determinant of subtype discordance in advanced breast cancer: a study of the SONABRE registry. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 331.	1.1	3
825	Circulating Tumor Cells and Breast Cancer: The Long and Winding Road Behind and Before Us. <i>Annals of Surgical Oncology</i> , 2022, 29, 2747.	0.7	1
826	Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542110731.	0.8	3
827	Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	27
828	Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3894-3912.	2.9	5
829	Blocking PI3K p110 $\beta$ Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 673-685.	1.5	6
831	Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 1033-1046.	1.2	5
832	Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment. <i>Cancers</i> , 2022, 14, 757.	1.7	15
833	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. , 2022, 236, 108108.		25
834	Palbociclib plus endocrine therapy significantly enhances overall survival of <math>HR^+</math> <math>HER2^-</math> metastatic breast cancer patients compared to endocrine therapy alone in the secondâ€line setting: A large institutional study. <i>International Journal of Cancer</i> , 2022, 150, 2025-2037.	2.3	16
835	Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases. <i>Current Oncology Reports</i> , 2022, 24, 343-350.	1.8	3
836	Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. <i>Molecular Oncology</i> , 2022, 16, 2057-2070.	2.1	4
837	Clinical Significance of <math>PIK3CA</math> and <math>ESR1</math> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. <i>Clinical Cancer Research</i> , 2022, 28, 1500-1506.	3.2	35
838	Lessons from microRNA biology: Top key cellular drivers of Autosomal Dominant Polycystic Kidney Disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166358.	1.8	1
839	A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1750-1753.	0.6	1
840	CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. <i>Future Oncology</i> , 2022, 18, 1143-1157.	1.1	8
841	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	3.2	22

#	ARTICLE	IF	CITATIONS
842	Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3891-3895.	1.1	12
843	Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	0.8	26
844	Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424.	1.5	9
845	Comprehensive Genomic Profiling for Therapeutic Decision and Identification of Gene Mutation in Uterine Endometrial Dedifferentiated Carcinoma. <i>Case Reports in Oncology</i> , 2022, 15, 46-55.	0.3	1
846	Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 215-225.	0.8	6
847	Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 828.	1.0	10
848	Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers. <i>Current Problems in Cancer</i> , 2022, 46, 100843.	1.0	1
849	Targeting PI3K/Akt signal transduction for cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 425.	7.1	302
850	Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. <i>American Journal of Cancer Research</i> , 2021, 11, 5155-5183.	1.4	1
852	Breast cancer management in 2021: A primer for the obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 30-45.	1.4	18
853	Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. <i>Cancer Medicine</i> , 2022, 11, 1796-1804.	1.3	8
854	Predictive molecular genetic tests in clinical oncology. <i>Voprosy Onkologii</i> , 2022, 68, 17-28.	0.1	0
855	Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review. <i>Cancers</i> , 2022, 14, 920.	1.7	10
856	Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer. <i>Cancers</i> , 2022, 14, 1133.	1.7	6
857	New and Emerging Targeted Therapies for Advanced Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2288.	1.8	55
858	PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 24.	2.3	9
859	In vitro anticancer effects of alpelisib against PIK3CA-mutated canine hemangiosarcoma cell lines. <i>Oncology Reports</i> , 2022, 47, .	1.2	9
860	HepaCAM PIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	3

#	ARTICLE	IF	CITATIONS
861	Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand. <i>Journal of Pathology and Translational Medicine</i> , 2022, , .	0.4	1
862	Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas. <i>Molecular Cancer</i> , 2022, 21, 50.	7.9	2
863	The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 535-541.	0.9	6
864	Molecular profiling leading to personalized treatment in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	1
865	PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. <i>Frontiers in Oncology</i> , 2022, 12, 819128.	1.3	135
866	Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab. <i>Frontiers in Oncology</i> , 2022, 12, 819818.	1.3	3
867	Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. <i>Frontiers in Oncology</i> , 2022, 12, 802579.	1.3	5
868	Biased Evaluation in Cancer Drug Trialsâ€”How Use of Progression-Free Survival as the Primary End Point Can Mislead. <i>JAMA Oncology</i> , 2022, 8, 679.	3.4	25
869	Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. <i>Genes and Diseases</i> , 2023, 10, 1367-1401.	1.5	152
870	Combinatorial Power of cfDNA, CTCs and EVs in Oncology. <i>Diagnostics</i> , 2022, 12, 870.	1.3	18
871	<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2â€”Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100370.	1.5	17
873	Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3794.	1.8	5
874	Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 592-602.	2.9	36
875	Racial Differences in Genomic Profiles of Breast Cancer. <i>JAMA Network Open</i> , 2022, 5, e220573.	2.8	11
876	A clinicianâ€™s handbook for using ctDNA throughout the patient journey. <i>Molecular Cancer</i> , 2022, 21, 81.	7.9	43
877	Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repairâ€”Related Genes. <i>JCO Precision Oncology</i> , 2022, 6, e2100140.	1.5	14
878	Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 253-264.	1.1	38
879	Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials. <i>Journal of Clinical Epidemiology</i> , 2022, 147, 132-141.	2.4	5

#	ARTICLE	IF	CITATIONS
880	New Advances in Targeted Therapy of HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 828438.	1.3	7
881	How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. <i>Life</i> , 2022, 12, 378.	1.1	8
883	Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. <i>PLoS ONE</i> , 2022, 17, e0264138.	1.1	100
884	BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer. <i>Tumori</i> , 2023, 109, 244-248.	0.6	8
885	Clinical Response to PI3K-Î± Inhibition in a Cohort of Children and Adults With PIK3CA-Related Overgrowth Spectrum Disorders. <i>Journal of Vascular Anomalies</i> , 2022, 3, e038.	0.1	4
886	Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment. <i>Cancers</i> , 2022, 14, 1405.	1.7	3
887	FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. <i>Molecules</i> , 2022, 27, 2259.	1.7	14
888	The potential of liquid biopsy in the management of cancer patients. <i>Seminars in Cancer Biology</i> , 2022, 84, 69-79.	4.3	55
889	Management Strategies for Hyperglycemia Associated with the Î±-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. <i>Cancers</i> , 2022, 14, 1598.	1.7	16
890	Toward Targeted Therapies in Oesophageal Cancers: An Overview. <i>Cancers</i> , 2022, 14, 1522.	1.7	3
891	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology</i> , The, 2022, 23, e89-e90.	5.1	4
892	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	2.0	25
893	Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience. <i>Pathology Research and Practice</i> , 2022, 232, 153820.	1.0	4
894	Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors. <i>Breast Cancer Research</i> , 2022, 24, 23.	2.2	5
895	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1020-1029.	1.9	3
896	Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers. <i>Targeted Oncology</i> , 2022, 17, 177-185.	1.7	1
897	In the literature: February 2022. <i>ESMO Open</i> , 2022, 7, 100411.	2.0	0
898	The New Era of Drug Discovery: The Power of Computer-aided Drug Design (CADD). <i>Letters in Drug Design and Discovery</i> , 2022, 19, 951-955.	0.4	25

#	ARTICLE	IF	CITATIONS
899	Aptamer-drug conjugates: New probes for imaging and targeted therapy. <i>Biosensors and Bioelectronics</i> , 2022, 10, 100126.	0.9	3
900	Are we ready to embrace novel therapeutic targets for women with AR-positive or AR-negative metastatic Triple-Negative Breast Cancer?. <i>Asia-Pacific Journal of Oncology</i> , 2021, , .	0.2	0
901	Can older patients adopt and maintain a ketogenic diet? An observational study in support of clinical trials in older patients. <i>Medicine (United States)</i> , 2021, 100, e28033.	0.4	3
903	WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	7
904	Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors. <i>Scientific Reports</i> , 2021, 11, 23548.	1.6	8
905	The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib. <i>Journal of Modern Oncology</i> , 2021, 23, 572-576.	0.1	3
906	Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13512.	1.8	6
907	Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. <i>Cancers</i> , 2022, 14, 196.	1.7	4
909	Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer. <i>Cureus</i> , 2021, 13, e20817.	0.2	1
910	Serial monitoring of genomic alterations in circulating tumor cells of ER $\alpha$ -positive/HER2 $\alpha$ -negative advanced breast cancer: feasibility of precision oncology biomarker detection. <i>Molecular Oncology</i> , 2022, 16, 1969-1985.	2.1	8
911	Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 24041.	1.6	6
913	Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice. <i>Meditsinskiy Sovet</i> , 2021, , 75-82.	0.1	2
914	Patient-Centered Diabetes Care of Cancer Patients. <i>Current Diabetes Reports</i> , 2021, 21, 62.	1.7	9
915	Lebensqualität und Lebensverlängerung durch endokrin kombinierte Tumorthherapie. <i>Frauenheilkunde Up2date</i> , 2021, 15, 497-513.	0.0	0
916	A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues. <i>Frontiers in Pharmacology</i> , 2021, 12, 785851.	1.6	6
917	The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. <i>Cancer Research</i> , 2022, 82, 2269-2280.	0.4	6
918	Nuclear translocation of p85 $\beta$ promotes tumorigenesis of PIK3CA helical domain mutant cancer. <i>Nature Communications</i> , 2022, 13, 1974.	5.8	13
919	Current and Developing Liquid Biopsy Techniques for Breast Cancer. <i>Cancers</i> , 2022, 14, 2052.	1.7	19



#	ARTICLE	IF	CITATIONS
920	Targeting mutations in cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	56
921	PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy. <i>Current Oncology</i> , 2022, 29, 2895-2908.	0.9	7
922	Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 101-111.	1.0	2
923	Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer. <i>Cancer Research and Treatment</i> , 2023, 55, 145-154.	1.3	2
940	Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 1809-1820.	3.2	22
941	The efficacy and safety of alpelisib in breast cancer: A real-world analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1152-1156.	0.5	6
942	FOXO transcriptional activity is associated with response to chemoradiation in EAC. <i>Journal of Translational Medicine</i> , 2022, 20, 183.	1.8	1
943	A phase III trial of alpelisib+trastuzumab ±fulvestrant versus trastuzumab+ chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancer. <i>Future Oncology</i> , 2022, 18, 2339-2349.	1.1	15
944	Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing. <i>Journal of Breast Cancer</i> , 0, 25, .	0.8	1
945	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. <i>Oncologist</i> , 2022, 27, 839-848.	1.9	18
947	Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. <i>PLoS ONE</i> , 2022, 17, e0267389.	1.1	7
948	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 2161.	1.7	15
949	Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study. <i>Journal of Modern Oncology</i> , 2022, 24, 12-23.	0.1	2
950	Catalytic Asymmetric Construction of CF3-Substituted Chiral sp <sup>3</sup> Carbon Centers. <i>Synthesis</i> , 2022, 54, 3708-3718.	1.2	10
951	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. <i>Nature Medicine</i> , 2022, 28, 946-957.	15.2	50
953	An atypical alpelisib-induced hyperglycemic hyperosmolar and diabetic ketoacidosis state: A case report and critical analysis of alpelisib-induced hyperglycemia management guidelines. <i>Annales D'Endocrinologie</i> , 2022, 83, 264-267.	0.6	2
954	Management of patients with hormone receptor-positive HER2-negative metastatic breast cancer: data of randomized trials and real-world evidence.. <i>Journal of Modern Oncology</i> , 2022, 24, 24-29.	0.1	1
955	Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 172-199.	0.5	6

#	ARTICLE	IF	CITATIONS
956	Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma. <i>HemaSphere</i> , 2022, 6, e727.	1.2	2
957	Comprehensive Genome-Scale Analysis of Esophageal Carcinoma With Esophageal Tissue-Resident Micro-Environment Discrepancy. <i>Frontiers in Microbiology</i> , 2022, 13, 859352.	1.5	1
958	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. <i>Breast Care</i> , 2022, 17, 421-429.	0.8	9
959	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2022, 35, 1227-1235.	2.9	5
960	Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma. <i>BMC Medicine</i> , 2022, 20, 175.	2.3	3
961	Management of Pheochromocytomas and Paragangliomas: A Case-Based Review of Clinical Aspects and Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 2591.	1.0	4
962	Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 581-588.	1.7	6
963	eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100240.	2.5	5
964	At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 471-485.	12.5	56
965	PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy. <i>Nature Medicine</i> , 2022, 28, 907-908.	15.2	1
966	Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. <i>BMC Medicine</i> , 2022, 20, 142.	2.3	55
968	Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 866-881.	4.0	13
969	Cell line models for drug discovery in PIK3CA-mutated colorectal cancers. <i>Medical Oncology</i> , 2022, 39, 89.	1.2	3
970	VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors â€” Efficacy, Safety, and Biomarker Results. <i>Clinical Cancer Research</i> , 2022, 28, 3256-3267.	3.2	28
971	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptorâ€”Positive, Human Epidermal Growth Factor Receptor 2â€”Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3246-3256.	0.8	190
972	The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103725.	2.0	1
973	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785.	0.6	37
974	Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes?. <i>Laboratoriums Medizin</i> , 2022, 46, 255-264.	0.1	6

#	ARTICLE	IF	CITATIONS
975	Developing dietary interventions as therapy for cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 452-466.	12.8	52
976	Therapeutics Targeting the Metastatic Breast Cancer Bone Microenvironment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
977	The History of Early Breast Cancer Treatment. <i>Genes</i> , 2022, 13, 960.	1.0	16
978	Using an Improved Residual Network to Identify PIK3CA Mutation Status in Breast Cancer on Ultrasound Image. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
979	NCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 561-565.	2.3	4
980	Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
981	Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
982	Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study. <i>British Journal of Cancer</i> , 2022, 127, 720-725.	2.9	17
983	Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
984	Cell Surface Markers and Their Targeted Drugs in Breast Cancer. <i>Current Protein and Peptide Science</i> , 2022, 23, .	0.7	0
985	Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-22.	0.9	9
986	PTEN&PI3K pathway alterations in advanced prostate cancer and clinical implications. <i>Prostate</i> , 2022, 82, .	1.2	20
987	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 851-864.	5.1	50
988	Somatic non-cancerous overgrowth syndrome of obscure molecular etiology: what are the causes and options?. <i>Journal of Molecular Medicine</i> , 0, , .	1.7	0
989	Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6320.	1.8	4
990	Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	1
991	Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. <i>Life</i> , 2022, 12, 829.	1.1	8
992	Targeting p85 <sup>Δ2</sup> nuclear translocation for the tumors with PIK3CA helical domain mutations. <i>Genes and Diseases</i> , 2022, 9, 1391-1393.	1.5	0

#	ARTICLE	IF	CITATIONS
993	Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 131, 105939.	0.8	5
994	To resect or not to resect?â€”the dilemma in oligometastatic breast cancer. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, .	0.7	0
996	S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962211052.	0.3	4
997	Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2022, 5, 498-510.	0.9	1
998	Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2022, 5, 727-48.	0.9	3
999	Molecular analysis of ascitic fluid cytology reflects genetic changes of malignancies of the ovary equivalent to surgically resected specimens. <i>Cancer Cytopathology</i> , 2022, 130, 640-649.	1.4	5
1000	Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. <i>Targeted Oncology</i> , 2022, 17, 355-368.	1.7	1
1001	Update on prognostic and predictive biomarkers of breast cancer. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 322-332.	1.0	20
1002	Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1004	RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. <i>Oncogene</i> , 0, , .	2.6	6
1005	Exploring new pathways in endocrine-resistant breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 337-361.	0.5	2
1007	ENDORSE: a prognostic model for endocrine therapy in estrogenâ€”receptorâ€”positive breast cancers. <i>Molecular Systems Biology</i> , 2022, 18, .	3.2	5
1008	Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
1009	Circulating tumor DNA: current challenges for clinical utility. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	50
1010	Synthetic Vulnerabilities in the KRAS Pathway. <i>Cancers</i> , 2022, 14, 2837.	1.7	3
1011	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 461-481.	0.6	6
1012	PERIORBITAL EDEMA ASSOCIATED WITH ALPELISIB. <i>Cancer Treatment and Research Communications</i> , 2022, , 100596.	0.7	1
1013	A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. <i>Cancer Research Communications</i> , 2022, 2, 570-576.	0.7	1

#	ARTICLE	IF	CITATIONS
1014	Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1015	Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors. <i>Viruses</i> , 2022, 14, 1372.	1.5	7
1016	Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1017	Elacestrant and the Promise of Oral SERDs. <i>Journal of Clinical Oncology</i> , 2022, 40, 3227-3229.	0.8	10
1018	Breast cancer in the era of precision medicine. <i>Molecular Biology Reports</i> , 2022, 49, 10023-10037.	1.0	19
1019	Alpelisib therapy: from theory to practice. <i>Meditinskiy Sovet</i> , 2022, , 57-64.	0.1	0
1020	Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. <i>Cancers</i> , 2022, 14, 3003.	1.7	3
1021	A Novel Role of IL13R $\alpha$ 2 in the Pathogenesis of Proliferative Vitreoretinopathy. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1022	Design, synthesis, docking study, and anticancer evaluation of novel bis-thiazole derivatives linked to benzofuran or benzothiazole moieties as PI3k inhibitors and apoptosis inducers. <i>Journal of Molecular Structure</i> , 2022, 1265, 133454.	1.8	12
1023	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	12
1024	Circulating cancer biomarkers: current status and future prospects. , 2022, , 409-443.		0
1025	Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211126.	1.4	3
1026	Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	12
1027	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 3205-3221.	0.8	43
1028	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. <i>Cancer Discovery</i> , 2022, 12, 2058-2073.	7.7	16
1029	Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
1030	Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy. <i>Cancers</i> , 2022, 14, 3374.	1.7	2
1031	Treating non-small cell lung cancer by targeting the PI3K signaling pathway. <i>Chinese Medical Journal</i> , 2022, 135, 1272-1284.	0.9	5

#	ARTICLE	IF	CITATIONS
1032	AACR Project GENIE: 100,000 Cases and Beyond. <i>Cancer Discovery</i> , 2022, 12, 2044-2057.	7.7	27
1033	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	0.6	204
1034	AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	24
1035	Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	11
1036	A p53â€“phosphoinositide signalosome regulates nuclear AKT activation. <i>Nature Cell Biology</i> , 2022, 24, 1099-1113.	4.6	26
1037	Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7889.	1.8	18
1038	Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	4
1039	Targeting micro-environmental pathways by PROTACs as a therapeutic strategy. <i>Seminars in Cancer Biology</i> , 2022, 86, 269-279.	4.3	7
1040	PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 0, , .	1.1	0
1041	Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3KÎ± specific inhibitors and ATP. <i>Computational Biology and Chemistry</i> , 2022, 99, 107726.	1.1	2
1042	Accelerating drug development in breast cancer: New frontiers for ER inhibition. <i>Cancer Treatment Reviews</i> , 2022, 109, 102432.	3.4	28
1043	New Drug Development and Clinical Trial Design by Applying Genomic Information Management. <i>Pharmaceutics</i> , 2022, 14, 1539.	2.0	3
1044	Current State of Cell Therapies for Breast Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2022, 28, 301-309.	1.0	5
1045	Response to Alpelisib in an Adolescent With <i>PIK3CA</i>-Mutated Metastatic Gastrointestinal Stromal Tumor. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
1046	Mechanisms and pathogenicity of the PI3K pathway: from basic research to clinical application. , 0, 6, 302-312.		0
1047	Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors. <i>Anticancer Research</i> , 2022, 42, 3913-3919.	0.5	4
1048	Hydrophobic Bile Salts Induce Pro-Fibrogenic Proliferation of Hepatic Stellate Cells through PI3K p110 Alpha Signaling. <i>Cells</i> , 2022, 11, 2344.	1.8	3
1049	Profiling disease and tissue-specific epigenetic signatures in cell-free DNA. <i>Laboratoriums Medizin</i> , 2022, 46, 283-294.	0.1	5

#	ARTICLE	IF	CITATIONS
1050	An Overview Regarding Pharmacogenomics and Biomarkers Discovery: Focus on Breast Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 1654-1673.	1.0	4
1051	Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. <i>Cancers</i> , 2022, 14, 3774.	1.7	10
1052	Inactivation of Hippo pathway characterizes a poor-prognosis subtype of esophageal cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	7
1053	Marker assessments in ER-positive breast cancers: old markers, new applications?. <i>Histopathology</i> , 2023, 82, 218-231.	1.6	3
1055	PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. <i>Cells</i> , 2022, 11, 2508.	1.8	42
1057	Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. <i>Diagnostics</i> , 2022, 12, 1903.	1.3	1
1058	Bioplatfroms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. <i>Biotechnology and Genetic Engineering Reviews</i> , 2022, 38, 339-383.	2.4	8
1059	Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones. <i>Pharmaceuticals</i> , 2022, 15, 1044.	1.7	4
1060	Bilateral Panuveitis and Exudative Retinal Detachments Associated with Alpelisib. <i>Case Reports in Oncology</i> , 2022, 15, 713-719.	0.3	4
1061	Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 4027.	1.7	4
1062	Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
1063	CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1064	Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1343-1360.	0.5	3
1065	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 597-617.	2.7	6
1066	Targeted therapy for breast cancer: An overview of drug classes and outcomes. <i>Biochemical Pharmacology</i> , 2022, 204, 115209.	2.0	38
1067	Clinicopathological characteristics and prognostic analysis of PIK3CA mutation in breast cancer patients in Northwest China. <i>Pathology Research and Practice</i> , 2022, 238, 154063.	1.0	1
1068	Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR) Tj ETQq0 009gBT /Overlock 10		
1069	The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 178, 103781.	2.0	3

#	ARTICLE	IF	CITATIONS
1070	Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119346.	1.9	13
1071	Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib. <i>Cancers</i> , 2022, 14, 4448.	1.7	4
1072	Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing. <i>Journal of the American Society of Cytopathology</i> , 2023, 12, 10-19.	0.2	3
1073	Controversial topics in metastatic HR+ /HER2- breast cancer: Guiding treatment by a modified Delphi approach. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1074	Druggable gene alterations in Japanese patients with rare malignancy. <i>Neoplasia</i> , 2022, 33, 100834.	2.3	0
1075	Therapeutics targeting the metastatic breast cancer bone microenvironment. , 2022, 239, 108280.		8
1076	Alpelisib - Induced Hyperglycemia. <i>Acta Endocrinologica</i> , 2022, 18, 115-117.	0.1	3
1077	Concomitant Radiation and Systemic Therapy in the Adjuvant and Metastatic Setting. , 2022, , 421-434.		0
1078	KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. <i>Journal of Cancer</i> , 2022, 13, 3209-3220.	1.2	10
1079	Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211136.	1.4	34
1080	Bioanalysis of alpelisib using liquid chromatography-tandem mass spectrometry and application to pharmacokinetic study. <i>Journal of Analytical Science and Technology</i> , 2022, 13, .	1.0	2
1081	Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 229-237.	1.1	3
1082	Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis. <i>Cancer Diagnosis &amp; Prognosis</i> , 2022, 2, 585-591.	0.3	7
1083	The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. <i>Cancers</i> , 2022, 14, 4203.	1.7	5
1084	CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review). <i>International Journal of Molecular Medicine</i> , 2022, 50, .	1.8	15
1086	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q and A. <i>JCO Oncology Practice</i> , 2022, 18, 830-832.	1.4	2
1087	PI3K Inhibition for Squamous Cell Head and Neck Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2022, 28, 369-376.	1.0	0
1088	EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). <i>Future Oncology</i> , 2022, 18, 3481-3492.	1.1	8



#	ARTICLE	IF	CITATIONS
1089	Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies. <i>Cancers</i> , 2022, 14, 4665.	1.7	3
1090	PIK3CA mutation status, progression and survival in advanced HR <sup>+</sup> /HER2- breast cancer: a meta-analysis of published clinical trials. <i>BMC Cancer</i> , 2022, 22, .	1.1	9
1091	CircSEMA4B inhibits the progression of breast cancer by encoding a novel protein SEMA4B-211aa and regulating AKT phosphorylation. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	31
1092	Bench to bedside: research influencing clinical practice in breast cancer. <i>Diagnostic Histopathology</i> , 2022, 28, 473-479.	0.2	2
1093	Case report: Apelisis-induced Stevens-Johnson syndrome. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1094	High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	32
1095	Apelisis for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth. <i>Genetics in Medicine</i> , 2022, 24, 2318-2328.	1.1	9
1096	Breast cancer: an update review and future perspectives. <i>Cancer Communications</i> , 2022, 42, 913-936.	3.7	70
1098	Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10132.	1.8	33
1099	Synthesis and biological evaluation of new thiazolyl-urea derivatives as potential dual C-RAF/FLT3 inhibitors. <i>Medicinal Chemistry Research</i> , 2022, 31, 1862-1874.	1.1	0
1100	Apelisis Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment. <i>Genes</i> , 2022, 13, 1763.	1.0	0
1102	Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. <i>Clinical Cancer Research</i> , 2023, 29, 67-80.	3.2	11
1103	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19
1104	Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 4279.	1.7	2
1105	Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 2933-2948.	2.0	21
1106	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
1107	Targeted therapy in oncology. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2022, , 222-228.	0.1	0
1108	PI3K Isoform Immunotherapy for Solid Tumours. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 369-392.	0.7	1

#	ARTICLE	IF	CITATIONS
1109	Molecular Pathology of Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 264.	0.9	6
1110	Class I PI3K Biology. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 3-49.	0.7	0
1112	Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1309-1315.	1.0	4
1113	Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. <i>Journal of Personalized Medicine</i> , 2022, 12, 1746.	1.1	5
1114	A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	12
1115	Preoperative Systemic Therapy for Breast Cancer. <i>Surgical Clinics of North America</i> , 2023, 103, 201-217.	0.5	4
1117	Association between PIK3CA Mutations in Blood and Tumor-Infiltrating Lymphocytes in Peruvian Breast Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 3331-3337.	0.5	2
1119	APOBEC Mutational Signatures in Hormone Receptorâ€“Positive Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	6
1120	Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. <i>JCO Precision Oncology</i> , 2022, , .	1.5	7
1121	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
1122	The Present and Future of Clinical Management in Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5891.	1.0	7
1123	Development of PI3K± inhibitors for tumor therapy. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 8587-8604.	2.0	3
1124	Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. <i>Molecular Cancer</i> , 2022, 21, .	7.9	29
1126	Computational Design of Phosphatidylinositol 3-Kinase Inhibitors. <i>Assay and Drug Development Technologies</i> , 2022, 20, 317-337.	0.6	6
1129	Advances in the Management of Central Nervous System Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12525.	1.8	1
1130	PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative. <i>Journal of Personalized Medicine</i> , 2022, 12, 1793.	1.1	2
1131	Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier. <i>Cancers</i> , 2022, 14, 5132.	1.7	2
1132	FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years. <i>Processes</i> , 2022, 10, 2054.	1.3	35

#	ARTICLE	IF	CITATIONS
1133	Prevalencia de la mutación de PIK3CA en cáncer de mama en la Argentina y su asociación con variables clínicas-patológicas. , 2022, 26, .		0
1134	Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 1635.	3.4	3
1135	Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3K± selective inhibitors. <i>Bioorganic Chemistry</i> , 2023, 130, 106211.	2.0	6
1136	Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1138	Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103848.	2.0	4
1139	Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor±Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5066-5078.	3.2	5
1140	Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103866.	2.0	2
1141	Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients. <i>Heliyon</i> , 2022, , e11396.	1.4	0
1142	Omics analyses of a somatic <i>Trp53</i> <sup>R245W/+</sup> breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
1143	Co-encapsulation of PI3-K±/HDAC6 dual inhibitor and Navitoclax in Quatramer±,± nanoparticles for synergistic effect in ER±breast cancer. <i>International Journal of Pharmaceutics</i> , 2022, 628, 122343.	2.6	2
1144	Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 1056-1067.	3.2	7
1145	Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. <i>MedComm</i> , 2022, 3, .	3.1	21
1146	PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib. <i>British Journal of Cancer</i> , 2023, 128, 148-159.	2.9	11
1147	Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 345-368.	1.0	4
1148	Alpelisib-induced acute cholestatic hepatitis in a patient with metastatic breast cancer- a case report. <i>Current Problems in Cancer Case Reports</i> , 2022, 8, 100200.	0.1	0
1149	RAS: Circuitry and therapeutic targeting. <i>Cellular Signalling</i> , 2023, 101, 110505.	1.7	1
1150	The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer. <i>Advances in Biological Regulation</i> , 2023, 87, 100934.	1.4	1
1151	First-in-human phase Ia study of the PI3K± inhibitor CYH33 in patients with solid tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	4

#	ARTICLE	IF	CITATIONS
1152	Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2 <sup>+</sup> Breast Cancer. <i>Cells</i> , 2022, 11, 3545.	1.8	7
1153	Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 697-706.	1.4	2
1154	Beyond PI3Ks: targeting phosphoinositide kinases in disease. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 357-386.	21.5	27
1155	Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor <sup>+</sup> positive Breast Cancer. <i>Cancer Research Communications</i> , 2022, 2, 1569-1578.	0.7	2
1156	Cell-free Nucleic Acids in Cancer. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 669-686.	0.7	0
1157	Current Standard Clinical Predictive Markers. , 2022, , 873-894.		0
1158	Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 112, 102496.	3.4	18
1159	Breast Cancer Pathology in the Era of Genomics. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 33-50.	0.9	2
1160	Comparison of <i>PIK3CA</i> Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
1161	SGLT-2 Inhibitors in Cancer Treatment <sup>2</sup> Mechanisms of Action and Emerging New Perspectives. <i>Cancers</i> , 2022, 14, 5811.	1.7	24
1162	An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. <i>Investigational New Drugs</i> , 2023, 41, 70-75.	1.2	4
1163	Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
1165	Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 369-376.	1.1	2
1166	Development of a multiplex allele-specific qPCR approach for testing PIK3CA mutations in patients with colorectal cancer. <i>Heliyon</i> , 2022, 8, e11804.	1.4	1
1167	Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1168	BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1169	DNA methylation-based classification of sinonasal tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	22
1170	Trop-2 as a Therapeutic Target in Breast Cancer. <i>Cancers</i> , 2022, 14, 5936.	1.7	18

#	ARTICLE	IF	CITATIONS
1171	The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1203-1226.	1.9	1
1172	Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	2
1173	Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1174	Emerging Therapies for Breast Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2023, 13, a041333.	2.9	2
1175	Real clinical practice patterns of palbociclib usage in Russian Federation. <i>Meditinskiy Sovet</i> , 2022, , 30-35.	0.1	0
1176	&lt;i>&gt;PIK3CA&lt;/i>-mutated breast cancer: from research to clinical practice. <i>Meditinskiy Sovet</i> , 2022, , 148-153.	0.1	0
1177	Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 6100.	1.7	4
1178	IQ Motif Containing GTPase Activating Proteins (IQGAPs), A-Kinase Anchoring Proteins (AKAPs) and Kinase Suppressor of Ras Proteins (KSRs) in Scaffolding Oncogenic Pathways and Their Therapeutic Potential. <i>ACS Omega</i> , 2022, 7, 45837-45848.	1.6	4
1179	Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	12
1180	Immune subtype identification and multi-layer perceptron classifier construction for breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1181	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 7523.	1.0	1
1182	Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. <i>Oncologist</i> , 2023, 28, 220-229.	1.9	4
1183	Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases. <i>CNS Drugs</i> , 0, , .	2.7	4
1184	Deciphering the molecular landscape of metastatic lobular breast cancer. <i>EBioMedicine</i> , 2022, 86, 104385.	2.7	0
1185	Biomarkers and translational research approaches in breast cancer – an update. <i>Memo - Magazine of European Medical Oncology</i> , 2023, 16, 42-46.	0.3	2
1186	Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
1187	The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression. <i>Cancers</i> , 2023, 15, 135.	1.7	3
1188	Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. <i>Oncogene</i> , 2023, 42, 1951-1956.	2.6	4

#	ARTICLE	IF	CITATIONS
1189	PIK3CA is recurrently mutated in canine mammary tumors, similarly to in human mammary neoplasia. <i>Scientific Reports</i> , 2023, 13, .	1.6	7
1191	How I treat HER2-low advanced breast cancer. <i>Breast</i> , 2023, 67, 116-123.	0.9	5
1193	Predictive and prognostic biomarker testing in invasive breast cancer. <i>Diagnostic Histopathology</i> , 2023, , .	0.2	0
1194	Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 230-237.e1.	0.9	0
1195	Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. <i>Biomedicines</i> , 2023, 11, 109.	1.4	18
1196	Pharmacokinetics and Pharmacodynamic of Alpelisib. <i>Clinical Pharmacokinetics</i> , 2023, 62, 45-53.	1.6	4
1197	Discovery and biosynthesis of karnamicins as angiotensin converting enzyme inhibitors. <i>Nature Communications</i> , 2023, 14, .	5.8	10
1198	Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future. , 2023, , 73-98.		0
1199	Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2 <sup>+</sup> metastatic breast cancer: an observational study of the SONABRE Registry. <i>Lancet Regional Health - Europe</i> , The, 2023, 26, 100573.	3.0	5
1200	Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114183.	2.5	5
1201	Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited. <i>Cancers</i> , 2023, 15, 93.	1.7	4
1202	Evaluating immune response in vitro in a relevant microenvironment: a high-throughput microfluidic model for clinical screening. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 853-865.	0.5	0
1203	Metastatic Breast Cancer: Cytology Diagnosis with Implications for Treatment. <i>Journal of Molecular Pathology</i> , 2023, 4, 1-14.	0.5	3
1204	The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-8.	1.1	0
1205	Driver and targetable alterations in Chinese patients with small bowel carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6139-6150.	1.2	0
1207	Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	13
1208	Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor <sup>+</sup> Positive (HR+)/HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1719-1729.	3.2	12
1209	Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. <i>Annals of Oncology</i> , 2023, 34, 397-409.	0.6	10

#	ARTICLE	IF	CITATIONS
1210	Current clinically validated applications of liquid biopsy. , 2023, , 63-81.		0
1211	Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, .	2.5	3
1212	Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer. Diagnostics, 2023, 13, 470.	1.3	1
1214	Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Molecular Cancer, 2023, 22, .	7.9	40
1215	Recent advances of tanshinone in regulating autophagy for medicinal research. Frontiers in Pharmacology, 0, 13, .	1.6	3
1216	Liquid biopsy: a right tool in a right context?. , 2023, , 31-45.		0
1217	Primary breast osteosarcoma in a patient previously treated for ipsilateral invasive ductal carcinoma: An unusual case report with clinical and genomic features. Frontiers in Oncology, 0, 12, .	1.3	0
1218	Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. Cancers, 2023, 15, 703.	1.7	11
1219	CDK4/6 Inhibitorsâ€”Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers, 2023, 15, 1763.	1.7	4
1221	Deciphering breast cancer: from biology to the clinic. Cell, 2023, 186, 1708-1728.	13.5	72
1223	Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review. Toxicology in Vitro, 2023, 88, 105558.	1.1	0
1224	Alpelisib-induced thyroiditis in a patient with metastatic breast cancer: Is routine monitoring of thyroid function required?. Current Problems in Cancer Case Reports, 2023, 9, 100219.	0.1	0
1225	A robust and lightweight deep attention multiple instance learning algorithm for predicting genetic alterations. Computerized Medical Imaging and Graphics, 2023, 105, 102189.	3.5	2
1226	Molekulare Diagnostik und molekulares Tumorboard. , 2022, , 359-376.		2
1227	Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. Expert Review of Molecular Diagnostics, 2023, 23, 41-51.	1.5	1
1228	Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival. Neurosurgery, 2023, 92, 1183-1191.	0.6	0
1229	Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups. Modern Pathology, 2023, 36, 100123.	2.9	4
1230	Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal â€” U-PIK Project. Frontiers in Molecular Biosciences, 0, 10, .	1.6	0

#	ARTICLE	IF	CITATIONS
1231	Vascular malformations: An overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapy. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	3
1232	Comprehensive analysis of NT5DC family prognostic and immune significance in breast cancer. <i>Medicine (United States)</i> , 2023, 102, e32927.	0.4	2
1233	Development and safety of PI3K inhibitors in cancer. <i>Archives of Toxicology</i> , 2023, 97, 635-650.	1.9	12
1234	DNMT3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	8
1235	Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2023, 28, 682-690.	1.9	3
1236	Dysregulation of Mitochondrial Translation Caused by <i>CBFB</i> Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer. <i>Cancer Research</i> , 2023, 83, 1280-1298.	0.4	1
1237	How I treat endocrine-dependent metastatic breast cancer. <i>ESMO Open</i> , 2023, 8, 100882.	2.0	6
1238	AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis. <i>Cancer Research</i> , 2023, 83, 1264-1279.	0.4	3
1239	Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1240	The Relationship between PIK3CA Mutation and Hormone Receptor Positive and HER2 Negative Breast Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 2724-2728.	0.0	0
1241	The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	4
1242	Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. <i>Journal of Pathology</i> , 2023, 260, 165-176.	2.1	1
1243	Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality. <i>Pharmaceuticals</i> , 2023, 16, 339.	1.7	4
1244	Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements. <i>Cancers</i> , 2023, 15, 1416.	1.7	7
1245	Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	25
1246	Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4522.	1.8	16
1247	Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides <i>BRCA1</i> and <i>BRCA2</i> as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies. <i>Anticancer Research</i> , 2023, 43, 967-981.	0.5	4
1249	Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. <i>Biomedicines</i> , 2023, 11, 735.	1.4	0



#	ARTICLE	IF	CITATIONS
1250	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 102-138.	0.5	14
1251	Molecular Profiling in Early ER+ Breast Cancer to Aid Systemic Therapy Decisions. Current Oncology Reports, 2023, 25, 491-500.	1.8	1
1252	Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer. Lung Cancer, 2023, 178, 229-236.	0.9	6
1253	Comparison of clinicopathological and genomic profiles in anal squamous cell carcinoma between Japanese and Caucasian cohorts. Scientific Reports, 2023, 13, .	1.6	4
1255	ER+, HER2- advanced breast cancer treated with tasisib and fulvestrant: genomic landscape and associated clinical outcomes. Molecular Oncology, 2023, 17, 2000-2016.	2.1	0
1256	Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA mutant cervical carcinoma via the PI3K/AKT pathway. Journal of Medical Virology, 2023, 95, .	2.5	5
1257	Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers, 2023, 15, 1766.	1.7	6
1259	PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. Journal of Physical Education and Sports Management, 2023, 9, a006255.	0.5	3
1260	Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets. Cancers, 2023, 15, 1855.	1.7	1
1261	Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. Ca-A Cancer Journal for Clinicians, 2023, 73, 480-515.	157.7	23
1262	Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer. Oncologist, 2023, 28, e488-e492.	1.9	1
1264	CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	6
1265	Involvement of APOBEC3A/B Deletion in Mouse Mammary Tumor Virus (MMTV)-like Positive Human Breast Cancer. Diagnostics, 2023, 13, 1196.	1.3	0
1266	Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date. OncoTargets and Therapy, 0, Volume 16, 189-196.	1.0	6
1267	The emerging role of PI3K inhibitors for solid tumour treatment and beyond. British Journal of Cancer, 2023, 128, 2150-2162.	2.9	18
1268	PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. Scientific Reports, 2023, 13, .	1.6	3
1269	Antitumor activity of the PI3K $\gamma$ -sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2+ breast cancer. Breast Cancer Research and Treatment, 0, , .	1.1	1
1270	Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA, AKT, PTEN mutated advanced solid tumors. Cancer, 2023, 129, 1919-1929.	2.0	1

#	ARTICLE	IF	CITATIONS
1271	Olaparib efficacy in patients with germline <scp>BRCA</scp>â€mutated, <scp>HER2</scp>â€negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> trial. International Journal of Cancer, 2023, 153, 803-814.	2.3	4
1272	Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. Cancers, 2023, 15, 2015.	1.7	3
1274	Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. Cancer Cell, 2023, 41, 660-677.e7.	7.7	7
1275	Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications. Cancer Medicine, 2023, 12, 11672-11685.	1.3	5
1276	Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. Medical Radiology, 2023, , .	0.0	0
1278	Second-line Endocrine Therapy of Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis. Current Cancer Drug Targets, 2023, 23, .	0.8	0
1279	N-acetylcysteine overcomes NF1 loss-driven resistance to PI3KÎ± inhibition in breast cancer. Cell Reports Medicine, 2023, 4, 101002.	3.3	3
1280	Computational pathology to improve biomarker testing in breast cancer: how close are we?. European Journal of Cancer Prevention, 2023, 32, 460-467.	0.6	4
1281	Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3KÎ± inhibitors. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	1
1282	Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases. Current Treatment Options in Oncology, 0, , .	1.3	4
1283	Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis. International Journal of Technology Assessment in Health Care, 2023, 39, .	0.2	0
1284	Biomarkerâ€based Bayesian randomized clinical trial design for identifying a target population. Statistics in Medicine, 0, , .	0.8	0
1285	Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation. Life Sciences, 2023, 324, 121708.	2.0	3
1287	Targeted therapy. , 2023, , 205-411.		0
1289	Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions. Oncologist, 2023, 28, e493-e497.	1.9	2
1353	Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges. Journal of Medicinal Chemistry, 2023, 66, 8339-8381.	2.9	13
1356	Omics in Precision Medicine. , 2023, , 237-263.		1
1358	Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2023, 201, 161-169.	1.1	0

#	ARTICLE	IF	CITATIONS
1364	Zukunftspotenziale der Labormedizin. , 2023, , 181-231.		0
1374	Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nature Reviews Cancer, 2023, 23, 673-685.	12.8	10
1381	Thiazole, a privileged scaffold in drug discovery. , 2023, , 1-19.		0
1401	Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. Npj Breast Cancer, 2023, 9, .	2.3	4
1409	CTCs in Early Breast Cancer. Current Cancer Research, 2023, , 463-490.	0.2	0
1415	Molecular testing in breast cancer. , 2024, , 303-318.		0
1422	Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer. Current Cancer Research, 2023, , 539-564.	0.2	0
1424	Clinical implementation of biomarkers and signaling pathway as novel targeted therapeutics in breast cancer. , 2023, , 27-56.		0
1487	The CDK4/6 inhibitor revolution â€” a game-changing era for breast cancer treatment. Nature Reviews Clinical Oncology, 2024, 21, 89-105.	12.5	4
1490	Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy. , 2024, 41, .		1
1500	A Closer Look at the Androgen Receptor (AR)- positive and AR-negative Metastatic Triple-Negative Breast Cancer: Can We Apply Novel Targeted Therapeutics?. , 2023, , 22-38.		0
1506	Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Cancer Treatment and Research, 2023, , 219-235.	0.2	1
1523	Diabetes Care in the Oncologic Population. Contemporary Endocrinology, 2023, , 355-370.	0.3	0
1528	FOXO3a-interacting proteinsâ€™ involvement in cancer: a review. Molecular Biology Reports, 2024, 51, .	1.0	0
1566	Artificial intelligence in cancer research and precision medicine. , 2024, , 1-23.		0